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ABSTRACT 
Strong experimental and clinical evidence indicates that the urokinase type 
plasminogen activation system is associated with many types of human cancer 
invasion and metastasis. A component of this system, which is over-expressed on 
cancer cell surfaces, urokinase plasminogen activator (uPA) is a potential marker that 
may be targeted for anticancer therapy. The naturally occurring inhibitor, plasminogen 
activator inhibitor type 2 (PAI-2), binds specifically to activated cell surface bound 
uPA. Thus, the overall aim of this project was to assess the viability of using human 
recombinant PAI-2 as a potential targeting device in future anti-cancer therapy 
projects. 
The dual colour flow cytometric analyses of breast and prostate cancer cell lines 
confirmed that metastatic HS-578-T, MDA-MB-231 and PCS cell lines expressed 
much higher levels of cell surface bound uPA than that of the non-metastatic MCF-7 
cell line. Assessment of cell surface endogenous PAI-2 expression showed a small 
difference between metastatic HS-578-T, MDA-MB-231 (higher) and non-metastatic 
MCF-7 cells (lower). Assessment of exogenous FITC conjugated PAI-2 on HS-578-T 
and MDA-MB-231 cells showed specific binding to cell surface bound uPA. 
Assessment of cell surface uPA and GFP expression on MDA-MB-231+GFP cells by 
flow cytometry showed that this transfected cell line maintained high uPA expression 
levels in addition to high GFP expression without further Geneticin selection. 
Examination by confocal microscopy visually confirmed that exogenous PAI-2 was 
internalized into MDA-MB-231-f-GFP cells presumably via uPA binding and 
endocytosis. This cell line will be used on murine breast cancer models as an easily 
detectable tissue in histological examinations in the future studies. 
An early stage breast cancer animal model was successfully obtained by subcutaneous 
inoculation of MDA-MB-231 cells into mammary fat pads of nude mice. 
In conclusion, the results of this project indicated the potential value of using human 
recombinant PAI-2 and the MDA-MB-231 cell lines for future targeted anti-cancer 
therapy projects. 
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1. INTRODUCTION 
1.1 AN OVERVIEW OF HUMAN CANCER INVASION AND METASTASIS 
1.1.1 Biological features of human cancer 
Carcinogenesis and metastasis are two key biological features of human cancer. 
Carcinogenesis refers to the process whereby normal cells are transformed so that 
they acquire the ability to grow without control and finally form the neoplasm or 
primary tumour. Whether these tumours are malignant or benign depends upon the 
ability of tumour cells to invade and spread (i.e. metastasize) throughout the body or 
not, respectively (Franks, 1997). 
Once the carcinogenic cellular phenotype has occurred and a neoplasm has formed, 
the process of tumour invasion and metastasis (i.e. malignancy) continues to take 
place under the influence of a variety of progression factors. These factors include: 
proteases such as urokinase plasminogen activator (uPA) (Andreasen et al., 1997) and 
cathepsin (Montcourrier, 1990), various angiogenic factors (Andreasen et al., 1997) 
such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) 
and tissue factor (TF), and growth factors (Dickson et al., 1992) such as epidermal 
growth factor (EGF) and transforming growth factor (TGF). 
The process of human cancer metastasis can be summarized by five successive steps: 
invasion, angiogenesis, intravasation, extravasation and metastasis formation 
(Fig. 1.1). During tumour growth, cancer cells invade local normal surrounding 
tissues. To grow beyond 1-2 mm in diameters, the neoplasm itself is invaded by 
'normal' vascular endothelial cells from nearby capillaries or venues. These 
endothelial cells will form the tumour vascular network (angiogenesis), which 'feed' 
the tumour allowing it to grow in size. Then, across the newly formed blood vessel 
wall, two-way invasive processes occur. In one direction immune cells egress from 
the vessels to infiltrate the primary tumour, in the other direction tumour cells 
penetrate into the capillary lumen (intravasation) and into the systemic circulation 
through the blood or lymphatic vessel. Finally, some of these malignant cells arrest in 
capillary beds at sites distant from the primary tumour. Here they may invade through 
vessel walls again (extravasation) into the surrounding tissue and form secondary 
tumours, i.e. metastases (Poste and Fidler, 1980). 
D 
Figure 1.1 Multiple processes of human cancer metastastasis. (A) Invasion, 
(B) Angiogenesis, (C) Intravasion, (D) Extravasion and Metastasis formation. 
1.1.2 The degradation of extracellular matrix (ECM) and human cancer invasion 
and metastasis 
Physiological invasive processes occur in the embryo and in the adult organism; e.g., 
during trophoblast implantation, formation of blood vessels (angiogenesis), 
extravasion of leukocytes in inflammation, and wound repair. Under pathological 
conditions invasion is a recurrent theme in the natural history of malignant tumour 
metastasis processes. A common feature of physiological and pathological cellular 
invasive processes is the ability of cells to cross biological barriers that are present at 
the interface between histologically distinct tissues. These include basement 
membranes (BM), such as are located at the dermal-epidermal junction and beneath 
capillary endothelium, and interstitial stroma, which is mostly represented in 
mesenchymal tissue (Poste and Fidler, 1980). BMs and interstitial stroma are highly 
organised structures composed of extracellular matrix (ECM), the components of 
which are secreted by neighbouring cells. These components include collagens (the 
major constituents of ECM and a family of fibrous proteins), glycoproteins (such as 
laminin, fibronectin, entactin and nidogen), proteoglycans, and glycosaminoglycans 
(Mignatti and Rifkin, 1993). The interaction of cells with ECM modulate cell 
adhesion, differentiation and morphogenesis, mitogenesis, cell motility, as well as 
selective exchange of molecules between cells and interstitial fluids (Farquahr, 1981). 
The degradation of ECM components during physiological and pathological invasive 
processes requires specific proteolytic enzymes (see review in Mignatti and Rifkin, 
1993). 
The ECM degrading proteinases can be subdivided into three classes: serine 
proteinases, metalloproteinases and cysteine proteinases. The serine proteinases 
include plasminogen activators (PAs), plasmin, leukocyte elastase, and cathepsin G. 
The PAs of the plasminogen activation proteolytic cascade system appear to play an 
important role in the processes of malignant cell invasion and metastasis (see section 
1.3 for detail). The PAs convert the zymogen plasminogen, a plasma protein 
ubiquitous in the body, to plasmin (see section 1.2.3 for detail). Plasmin is an enzyme 
with broad trypsinlike substrate specificity. In addition to its major role in blood in 
dissolving fibrin clots, it is also able to directly degrade several ECM components 
including proteoglycans, fibronectin, laminin, and type IV collagen (Plow et al., 
1991). Furthermore plasmin can directly activate pro-metalloproteinases (Carroll and 
Binder, 1999), the active forms of which degrade different collagen types, laminin, 
fibronectin, elastin and proteoglycans of ECM. Thus, plasmin initiates a potent 
proteolytic cascade and there is much evidence to indicate that the extracellular 
plasminogen activation cascade facilitates cancer cell invasion and metastasis via its 
pivotal role in ECM degradation. Prior to discussing the evidence for this, the 
components of the cascade will be described in detail below. 
1.2 THE PLASMINOGEN ACTIVATION CASCADE SYSTEM 
1.2.1 Overview of the plasminogen activation cascade system 
The plasminogen activation cascade is a complicated system of zymogens, active 
enzymes, activators, inhibitors and binding proteins, which interact in a highly 
organized manner to generate and subsequently regulate the broad spectrum serine 
protease, plasmin. This system functions primarily in fibrinolysis and extracellular 
matrix degradation. It is of central importance in the maintenance of proper 
haemostasis after blood coagulation, specifically in facilitating vascular fibrinolysis 
and in the control of wound healing (Binder, 1995). While the extent which this 
system contributes to other normal physiological processes such as ovulation, fertility, 
and embryogenesis is in question, as judged by results obtained with so called 'knock 
out" mice (Carmeliet et al., 1994; Bugge et al., 1995), there is abundant evidence that 
the coordinated expression of components of this system by both malignant tumour 
cells and normal cells within the local environment allows successful cancer cell 
invasion and metastasis (Dano et al., 1985, Andreasen et al, 1997) (refer to section 
1.3 for detail). 
1.2.2 Plasminogen 
Plasminogen is present in blood and most extracellular fluids. It is synthesized in the 
liver (Raum et al., 1980), and is maintained at a stable plasma concentration of 2.0 
|iM (Ponting et al., 1992). Native human plasminogen is synthesized as a single chain 
glycoprotein containing 810 amino acids, from which a 19-residue signal peptide is 
excised during secretion. The mature form of plasminogen is therefore 790 amino 
acids in length, with a molecular weight of 92 kDa and a glutamic acid residue at the 
amino terminus (referred to glu-plasminogen) (Sottrup-Jensen et al., 1978). 
Circulating human glu-plasminogen is glycosylated with an 0-linked tetrasaccharide 
at Thr346, whilst differential N-linked glycosylation at Asn289 produces two 
glycoforms (Hayes and Castellino, 1979). This difference in glycosylation influences 
the affinity of plasminogen for fibrin, a2-antiplasmin and cellular receptors and also 
its rate of activation (Ponting et al., 1992). 
Various aspects of the biological activity of plasminogen are facilitated by three 
distinct protein domains. First is a 12KDa N-terminal pre-activation domain, which is 
critical for maintenance of the tightly closed spiral conformation of circulating glu-
plasminogen through non-covalent interactions with other domains of the protein (see 
review in Ponting et aL, 1992). Removal of this domain via plasmin or urokinase type 
plasminogen activator (uPA) catalyzed proteolysis at positions Arg67-Met68, Lysye-
Lys77, and Lysvv-Valvg results in formation of the second in vivo species of 
plasminogen known as lys-plasminogen. Lys-plasminogen has a more open 
conformation than glu-plasminogen and hence a faster activation rate and higher 
specific activity once converted to plasmin (Hoylaerts et al., 1982; also see review in 
Ponting et al., 1992). Secondly, binding of plasminogen to various cellular receptors 
and ECM proteins is mediated by lysine binding site (LBS) motifs found in the five 
triple disulfide-bonded loop structures known as kringles in the plasminogen binding 
domain (Sottrup-Jensen et al., 1978). Thirdly, the C-terminal 230 amino acids of 
plasminogen, known as the protease domain, contain the plasmin catalytic triad 
(His602, Asp645, Ser74o) which hydrolyses peptide bonds on the C-terminal side of 
lysine or arginine residues (see review in Ponting et al., 1992). Activation of the 
inactive zymogen (i.e. plasminogen) to active plasmin is facilitated by cleavage of 
plasminogen at Argseo-Valsei by plasminogen activators, forming a twin chain 
molecule composed of a heavy chain (65KDa, containing the pre-activation and 
kringle domains) disulfide bonded to a light chain (25KDa, containing protease 
domain) (Pollanen et al., 1991). 
1.2.3 Plasminogen activators (PAs) 
Plasminogen activators (PAs) are enzymes capable of promoting the conversion of 
inactive zymogen plasminogen to its active form plasmin. They are found in most 
tissues and body fluid in two major characterized forms: urokinase-type (uPA) and 
tissue-type (tPA) plasminogen activators. Other plasminogen activators include 
bacterial streptokinase and staphylokinase, and some other vertebrate plasminogen 
activators (Dano et al., 1985). 
These two major PAs belong to the family of serine proteases. They are encoded by 
different genes and have distinctive structural and functional properties, despite 
showing 40% homology at the amino acid level (Degen et al., 1991). The u-PA gene 
is located on chromosome 8, and that of t-PA on chromosome 10 (Rajput et al., 1985). 
These genes encode a 2.5kb mRNA which is translated into a 53 KDa glycoprotein 
for uPA, and a 2.7 kb mRNA which is translated into a 70 KDa glycoprotein for tPA. 
Structural differences between uPA and tPA include the absence of the second kringle 
domain in uPA and the 43-residue-amino-terminal finger domain present in tPA (van 
Zonneved et al., 1986). 
Both PAs are produced as inactive single chain zymogens (sc-uPA and sc-tPA) which 
are activated via cleavage by plasmin and other proteases to the active two-chain form 
PAs (tc-uPA and tc-tPA). The conversion of sc-uPA to an active tc-uPA occurs by 
cleavage of the peptide bond Lysisg-Heisg (Pollanen et al., 1991). In vitro, this 
conversion has been reported to be catalyzed by a number of different proteinases. 
These include plasmin (Dano et al., 1985), plasma kallikrein and blood coagulation 
factor Villa (Ichinose et al., 1986), T cell associated serine proteinase (Brunner et al., 
1990), cathepsin B (Kobayashi et al., 1991), cathepsin L (Goretzki et al., 1992), and 
human mast cell tryptase (Stack and Johnson, 1994). The conversion of the virtually 
inactive sc-uPA to the active tc-uPA by catalytic amounts of plasmin is a crucial 
regulatory step in the uPA pathway of plasminogen activation, since it not only 
provides active uPA but also enables an autocatalytic acceleration of uPA formation 
(Mayer, 1990). 
uPA binds to specific cell membrane-anchored receptors (uPAR) and is therefore 
primarily involved in cell based proteolysis that entail dissolution of ECM. The active 
tc-uPA consists of a light 'A chain corresponding to its amino terminal region and a 
heavy carboxy terminal 'B' chain linked together by a disulfide bridge (Dano et al., 
1985). 'A chain has a kringle domain and a growth-factor-like domain (termed K-G 
subunits), corresponding 'B' chain has the catalytic serine protease domain (PD). 
Following an additional proteolytic process, tc-uPA is further cleaved into an amino 
terminal fragment (ATF) and low molecular weight uPA (LMW-uPA). Whereas 
LMW-uPA is primarily involved in cellular proteolysis, tissue remodeling, embryonic 
development, zymogen and growth factor activation to promote tumour invasion and 
metastasis, ATF following its binding to uPA cell surface receptor (uPAR) can 
promote cell proliferation, migration and adhesion (Fig. 1.2). 
^ Proteolysis 
^ Tissue remodelling sc-uPA 
LMW-uPA y 
tc-uPA 
• Cell proliferation 
^ Embryonic development 
• Zymogen and growth factor activation 
^ C a n c e r invasion a n d metas tas i s 
ATF • uPAR activation Cell migration 
Cell adhesion 
Fig 1.2 Model of processing and function of urokinase plasminogen activator (uPA). 
The single chain uPA (sc-uPA) is converted into two chain uPA (tc-uPA) which undergoes 
another step of proteolysis to form low molecular weight uPA (LMW-uPA) and its amino 
terminal fragment (ATF) to elicit diverse effects either directly or following the binding of 
ATF with uPAR 
The central role of the uPA in tumour biology is becoming more and more evident and 
considered important in local tumour growth, invasion and metastasis (Duffy, 1993) 
(also see section 1.3). 
Fibrinolysis is another in vivo function of the plasminogen system. tPA primarily 
functions in this process by which fibrin is removed from the intravascular system 
after it has completed its homeostatic task (Dano et al., 1985), as tPA must be bound 
to fibrin for its full activity to be expressed (Chucholowski et al., 1991). 
PA expression and activity can be regulated at many levels. Numerous hormones, 
growth factors, and cytokines, exhibiting a wide variation that is dependent on cell or 
tissue type studied, govern synthesis and release of both PAs (Pollanen et al., 1991). 
Upon secretion, PA activity can be regulated positively or negatively by different 
components (Carrol and Binder, 1999). PAs activity is subject to a variety of specific 
and fast acting serine protease inhibitors (serpins) present in the extracellular fluid 
referred to as plasminogen activator inhibitors (PAIs) (Pollanen et al., 1991). 
1.2.4 Plasminogen activator inhibitors (PAIs) 
1.2.4.1 Overview 
hi the extracellular compartment, the secreted plasminogen activators (PAs) become 
subject to the specific, fast acting plasminogen activator inhibitors (PAIs). Currently 
there are four classes of PAIs: PAI-1, PAI-2, PAI-3 (or named Protein C Inhibitor, 
PCI), and protease nexin 1 (PN-1) (Pollanen et al., 1991). The PAIs belong to the 
serin protease inhibitors (serpins) superfamily, and are placed in the arginine-serpin 
subgroup due to the arginine (Arg) residue at PI position of their reactive centers. 
Despite uncertainty over the precise nature of the serpin inhibitory mechanism, it is 
clear that inhibition involves insertion of the reactive center loop (RCL) into p-sheet 
A of the serpin and transition to a more stable thermodynamic state, known as the 
relaxed form of the inhibitor (Gettins et al., 1992). Of these four classes, PAI-1 and 
PAI-2 are highly specific for PAs when compared to PAI-3 and PN-1, which both 
have broader specificity profiles (Pollanen et al., 1991). 
PAI-1 and PAI-2 have many different properties and these are presented in Table 1.1. 
PAI-1 inhibits single-chain tPA (sc-tPA), two-chain tPA (tc-tPA), and two-chain uPA 
(tc-uPA), but not single chain-uPA (sc-uPA), by forming tight sodium dodecyl sulfate 
(SDS) stable 1:1 molar complexes in a very fast reaction involving the active site of 
the enzyme (Pollanen et al., 1991). PAI-2 is an efficient inhibitor of active tc-uPA, 
forming a slowly dissociable SDS-stable 1:1 complex with uPA (rate constant 1x10^ 
(Kruithof et al., 1995). Since fibrin-bound tPA is protected from inhibition by 
PAI-2 and is 10,000 times slower in inhibiting sc-tPA than PAI-1, PAI-2 is probably 
less likely to be involved in the physiological regulation of tPA (Kruithof et al., 1995). 
Table 1.1 Comparison of human PAI-1 and PAI-2 properties (modified from 
Pollanen et al., 1991) 
Characteristic PAI-1 PAI-2 
Molecular weight 46-47 KDa 47 KDa (intracellular) 
60 KDa (glycosylated) 
Amino acid residues 379 415 
mRNA 3.0/2.2 Kb 2.0 Kb 
Chromosomal site 7 18q21-2 
Synthesized by Endothehal cells, Placental trophoblasts, 
Many types of cells monocytes, etc. 
Principal enzyme specificity tPA and uPA uPA 
Binding protein Vitronectin None known 
Latent inactive foiui Yes No 
Effect of sodium dodecyl sulfate Reactivates Inactivates 
Increased plasma concentrations Septic Shock Pregnancy 
m 
3 0 0 0 9 0 3 2 5 4 7 9 8 1 
1.2.4.2 Plasminogen activator inhibitor type 1 (PAI-1) 
PAI-1 is a single chain 46 to 54 kDa glycoprotein encoded by 3.0 and 2.2 kb mRNAs, 
the shorter transcript possibly being generated by modified polyadenylation. The 
human PAI-1 gene of 12.2 kb is located on chromosome 7. The amino acid sequence 
deduced from the PAI-lcDNA contains 379 residues, three potential glycosylation 
sites, but no cysteine residues (Pollanen et al., 1991). 
PAI-1 has significant homology with members of the serpins family. Like other 
serpins, PAI-1 has a reactive center located on a highly strained, exposed loop, the 
RCL, near the C-terminus of the molecule. The 'reactive center' of PAI-lcontains the 
'bait' peptide bond between residues Arg346 and Met347, i.e. the Pl -Pl ' residues. This 
bond mimics the Argseo-Valsei bond of plasminogen, which is the bond cleaved by the 
plasminogen activators during the activation of plasminogen to plasmin. On the basis 
of the mechanism of the action of other serpins, it has been postulated that PAI-1 
binds specifically to the plasminogen activators like substrates (Seetharm R, 1992). 
PAI-1 is secreted as an active antiprotease, but it rapidly, spontaneously converts to an 
inactive latent form. Latent PAI-1 is uncleaved but does not show any inhibitory 
activity towards target protease, i.e., tPA. In this state, the reactive center loop of PAI-
1 forms a sixth and central strand (known as s4A) of (3 sheet A, which is now 
inaccessible to target protease. However, the term 'latent' is used because inhibitory 
activity can be regained after a cycle of denaturation and renaturation (Tucker et al., 
1995). Indeed this structure is superimposable on the structure of cleaved ai-
antitrypsin with the exception that the Pl -Pl ' bond is still intact (Gettins et al., 1992). 
Active PAI-1 could be stored at -70°C for months with minimal loss in its activity and 
negligible conversion to the latent form. However, the PAI-1 lost about 50% of its 
activity after 2 days at 25 or after 2 hours at 37 due to conversion to the latent 
form. Significant conversion to the latent form also occurred at 4 (Seetharm, 1992, 
Reilly et al., 1990). 
PAI-1 is produced by many cell types such as endothelial cells, fibroblasts, vascular 
smooth muscle cells, hepatocytes, hepatoma cells, mammary cells, melanoma cells, 
fibrosarcoma cells and platelets et al. (Loskutoff, 1991). It is also present in plasma 
(Andreasen et al., 1990). PAI-1 is found associated with vitronectin in plasma 
(Preissner et al., 1993) and ECM (Ciambrone and McKeown-Longo, 1990). The 
somatomedin B domain of vitronectin was identified as the PAI-1 binding site 
(Seiffert and Loskutoff, 1991). Binding of vitronectin not only stabilized PAI-1 in an 
active configuration (presumably by holding the loop out of the A sheet), but also 
conferred on PAI-1 other inhibitory properties such as binding to thrombin (Pollanen 
etal., 1991). 
PAI-1 accumulates in the ECM and can be significantly enhanced by exposure of cells 
to hormones and growth factors (such as transforming growth factor a, TGF-a) 
(Laiho M et al., 1986). In fact, PAI-1 secretion and/or gene expression have been 
demonstrated to be regulated by several effectors, many of which regulate the 
expression of PAs as well. They include interleukin-1, thrombin, bacterial endotoxin, 
basic fibroblast growth factor, phorbol myristate acetate, dexamethasone, tumour 
necrosis factor a , and platelet-derived growth factor etc.. PAI-1 appears to be the 
primary regulator of fibrinolysis in the vasculature. The increased plasma amounts of 
i l 
PAI-1 and PAI-2 during normal pregnancy probably contribute to the maintenance of 
the overall balance of the fibrinolytic system, as uPA and tPA concentrations are 
increased as well. High levels of PAI-1 were detected in the plasma of patients with 
severe preeclampsia, with a positive correlation to the severity of placental damage, 
and with adult repiratory distress syndrome (Pollanen et al., 1991). 
1.2.4.3 Plasminogen activator inhibitor type 2 (PAI-2) 
PAI-2 was originally reported to be produced in the placenta and by cells of the 
monocyte / macrophage lineage (Pollanen et al., 1991). However, recent studies have 
shown that PAI-2 is expressed by many cell types. These include stimulated human 
endothelial cells (Schleef et al., 1988), cultured vascular smooth muscle cells (Laug et 
al., 1989), fibroblasts from fetal lung and foreskin (Kumar et al., 1992), normal 
human epidermis and cultured epidermal keratinocytes (Jensen et al., 1995), epithelial 
cells of the murine hair follicle and nail apparatus (Lavker et al., 1998), and numerous 
other stratified squamous epithelial cells (Risse et al., 1998). Under normal conditions 
levels of PAI-2 in plasma or serum are below detection limits. Initially detectable PAI-
2 was consistently found in blood plasma during pregnancy (Nilsson et al., 1986), 
more recent findings suggest a much wider tissue distribution than initially thought. 
These include dermal and epidermal layers of the skin (Lyons-Giorgano et al., 1994), 
blood plasma in patients with myelomonocytic and acute monocytic leukaemia (Wada 
et al., 1993) and with various liver diseases (Leiper et al., 1994), human gingival 
cervicular fluid and whole saliva (Kinnby B, 1993). 
The PAI-2 gene is located on the long arm of chromosome 18 between bands q21-23. 
It spans 16.5 kb and has eight exons and seven introns. When compared to the genes 
of two other serpins, PAI-1 and ovalbumin, the PAI-2 gene is shown to be 
significantly different to the gene encoding PAI-1 but has a very similar structure 
(37% homology) to that of hen ovalbumin gene (Webb et al , 1987, Ye et al., 1989). 
The PAI-2 cDNA encodes a mRNA transcript of approximately 2.0 kb. PAI-2 
expression can be regulated at both gene level and mRNA level. This expression is 
modulated by a large number of factors including cytokines, growth factors and 
hormones (Kruithof et al., 1995) (Fig. 1.3). 
Growth Factors 
EGF, M-CSF, 
GM-CSF 
cAMP J=. 
Steroid hormones 
Dexamethasone, Vitamii^D 
Cytokines 
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Tumour promoters 
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Figure 1.3 Factors influencing PAI-2 gene expression. indicates up regulation, 
indicates down regulation. 
The primary structure of human PAI-2 is a single chain polypeptide comprised of 415 
amino acids with a characteristic serpin reactive center formed by the Arg380-Thr381 
bond (Fig. 1.4) (Antalis et al., 1988). It is an alpha globulin molecule that is stable at 
pH 5.0-7.5 and exits in two distinct isoforms, both expressing inhibitory activities. 
These are a non-glycosylated 47 kDa form, mainly found intracellularly, with an 
isoelectric point of 5.0, and a 60 kDa glycosylated form, mainly found extracellular, 
with an isoelectric point of 4.4 (Mikus et al., 1993). Both the cytosolic and secreted 
forms are encoded by same 2.0 Kb mRNA, a process referred to as co-translational 
facultative translocation (Belin, 1993). The relative distribution of the two forms of 
PAI-2 seems dependent on cell type and differentiation state as well as culture 
conditions (Mikus et al., 1993). Localization of active PAI-2 to a third topological 
location, the surface of many non-transformed cell types (e.g. keratinocytes, 
trophoblasts) has also recently been described (Kruithof et al., 1995). The localization 
of PAI-2 to more than one topological site may be the result of inefficient 
translocation of the protein into the secretary pathway. Secreted proteins generally 
contain a hydrophobic signal sequence. PAI-2 is an exception as it contains an 
uncleaved signal peptide. This signal sequence of PAI-2 contains an asparagine 
hydrophobic core and two glutamine residues in the N-terminal region that dictates 
poor secretion of the PAI-2 protein (Belin, 1993). Another unique protein feature of 
PAI-2 is the presence of an extended loop between the C and D helices. The function 
of this loop is unknown but it may be a functional domain that allows PAI-2 to take 
part in binding reactions without affecting its inhibitory activity (Jenson et al., 1994). 
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Figure 1.4 PAI-2 amino acid sequence. Positions of structural elements, e.g. 
p-sheet strands, a-helices, C-D loop, RCL, and reactive bond, which is 
designated by a dashed line between the PI (Argaso) and PI ' (Thrsgi) residues 
(SwissProt AC# P05120; Ye et al. 1987), are all shown as above. 
Similar to other serpins, PAI-2 contains an reactive center loop (RCL) near the C 
terminus which, on proteolytic cleavage, is inserted into central P-sheet A of PAI-2, 
resulting in a conformational change from a stressed to relaxed (S-R) state 
(Wilczynska M et al., 1995). When PAI-2 interacts with target proteases (e.g. uPA and 
tPA), it is cleaved in its RCL by proteases, then a stable enzyme-inhibitor complex is 
formed, and the proteases are irreversibly inhibited. PAI-2 may also be cleaved by a 
proteinase that rapidly escapes from the inhibitor after cleavage, thus this protease 
retains its proteolytic activity while generating an inactive inhibitor; in this case PAI-2 
is acting not as an inhibitor but as a substrate of the protease (Kruithof et al., 1995). It 
has been suggested by Kruithof et al. (1995) that the unexpected intracellular 
localization of PAI-2 may be due to the interaction of PAI-2 with an unidentified 
cytoplasmic protease. For instance, the corneal epithelial PAI-2 was shown to be 
cleaved by an unidentified cytoplasmic protease (Williams, 1999). 
Although the role of PAI-2 as the primary in vivo inhibitor of uPA is clear, the exact 
physiological roles of PAI-2 in the modulation of proteolytic activity remain to be 
clarified (Kruithof et al., 1995). PAI-2 (also PAI-1) antigen levels are known to rise 
progressively throughout normal pregnancies resulting in a decrease of plasminogen 
activation. Distinct PAI-2 and PAI-1 levels are noted in pregnancies complicated 
preeclampsia (PE) and / or intrauterine growth retardation (lUGR). These differences 
indicates that an increase in PAI-1 plasma level may act as a marker for PE, while 
decreased PAI-2 plasma level as a marker for lUGR (Kruithof et al., 1995). PAI-2 
may be involved in other physiological and pathological events, in which uPA-
mediated proteolysis plays an important role, including tissue remodeling, wound 
healing, epidermal differentiation, leukocyte migration, programmed cell death (i.e. 
apoptosis), inflammation and mmour invasion (Kruithof et al., 1995) (see section 1.3 
& 1.4 for detail). 
1.2.5 Urokinase plasminogen activator receptor (uPAR) 
The cell surface uPAR has been isolated from human and rodent cell lines (Rabbani et 
al., 1994; Roldan et al., 1990). The gene encoding uPAR located on the long arm of 
chromosome 19 can express multiple isoforms of uPAR due to alternate splicing. 
uPAR is a 50-60kDa cysteine rich highly glycosylated protein. Due to the presence of 
cysteine residues, uPAR can be divided into three domains, domain 1, 2 and 3 as 
numbered from the amino-terminal, which are homologous to other members of GPI 
anchored proteins such as LY-6, squid glycoprotein (SgP-2), and viral protein HVS-5 
(Dano et al., 1994). It is linked to the plasma membrane by the glycosyl 
phosphatidylinositol (GPI) anchor located in its carboxyl-terminal domain 3 (Fig. 1.6; 
Plough et al., 1991). 
Binding of uPA to its speciñc cell surface GPI anchored receptors (uPAR) is 
important for the localization of uPA catalyzed plasminogen activation. Binding is 
rapid, saturable, and with a high affinity of 10"̂ ° M. The binding of uPA to the 
receptor occurs at its growth factor domain in the 'A chain (as described in section 
1.2.2); it does not involve the catalytic site of uPA. Single chain uPA (sc-uPA) binding 
to the cellular receptors is followed by conversion of the bound enzyme to active two-
chain uPA (tc-uPA) on the cell surface (Fig. 1.6). Therefore receptor bound uPA 
retains its enzymatic activity and still maintains its susceptibility to be inhibited by 
PAI-1 or PAI-2 (Mayer, 1990). PAI-1 and PAI-2 will bind to the cell surface 
associated uPA-uPAR complex by forming an enzymatically inactive trimeric 
receptor-protease-inhibitor complex. Then the PAIs trigger a series of events leading 
to the internalization of the uPA-uPAR-PAI complex. The complex would be degraded 
in the lysosomes and the uPAR is recycled back to cell surface (Nykjaer et al., 1997; 
Mignatti et al., 1993). 
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Figure 1.5 The structure and interactions of human uPAR with sc-uPA and 
tc-uPA on cell surface. Human uPAR contains 3 domains (numbered as 1, 2 
and 3 from N-terminus). The C-terminus of uPAR is attached to the cell 
membrane via a GPI anchor, which may be involved in intracellular signal 
transduction. The domain 1 contains binding sites for single-chain and two-
chain uPA (sc-uPA and tc-uPA). uPA contains 3 domains: G, growth domain; 
K, kringle domain; SPD, serine proteinase domain. After binding to the domain 
1 of uPAR on the cell surface, sc-uPA is cleavaged by plasmin and other 
proteinase at the peptide bond of Lysl58-Ilel59. This cleavage forms the active 
tc-uPA that contains two chains of polypeptides, the SPD and K-G subunits, 
linked by a disulfide bond. Cell surface receptor bound uPA is functional in 
activation of plasminogen to plasmin during focalised extracellular proteolysis 
(modified from Behrendt et al., 1991). 
1.2.6 Regulation of plasmin generation 
The broad substrate specificity of plasmin means strict control is required to limit 
activation to only physiologically appropriate times and sites. Regulation of plasmin 
generation by the plasminogen activation system is therefore intricate and 
multifaceted at multiple levels including gene translation, pro-enzyme secretion, etc.. 
At the level of activation, not only can plasminogen activators' activity be regulated 
either positively (as fibrin or cell surface receptors) or negatively (as PAIs), but also 
the local microenvironment plays an important role. Inhibitors of plasmin also exist: 
a2-antiplasmin, a2-plasmin inhibitor (a2-PI) and a2-macroglobulin (a2-M) are fast 
acting protease inhibitors, which rapidly inactivate any plasmin found free in solution 
(Veronica and Bernd, 1999). The presence of these circulating inhibitors may limit the 
physiological effectiveness of any plasmin-mediated extracellular activation events, 
however, local concentrations of plasmin may be sufficiently high to overcome local 
levels of inhibitors, permitting pericellular activation (Castellino, 1995). 
A second component of plasmin regulation involves manipulating the amount of 
plasminogen available for activation to plasmin (Castellino, 1995). Invasive 
procedures such as surgery or the use of oral contraceptives result in a decrease in the 
amount of circulating histidine-rich glycoprotein, a plasminogen binding protein 
known to reversibly bind 40% of the circulating plasminogen, thereby causing an 
increase in the amount of plasminogen available for activation to plasmin (Castellino, 
1995). 
A third element of plasmin regulation involves the cell surface plasminogen receptors 
and uPA receptor (uPAR) (Vaheri et al., 1990). The existence of plasma membrane 
binding sites for uPA, plasminogen and plasmin points to the cell surface as the site of 
assemblage of a powerful proteolytic system. Two steps in the urokinase plasminogen 
activation system are dramatically enhanced by this process. Firstly activation of sc-
uPA is markedly increased when it is receptor-bound and when plasminogen is 
simultaneously present on the cell surface, and this in turn accelerates plasmin 
formation (Ellis et al., 1989). Plasmin on the cell surface is protected from a2-
antiplasmin in plasma and extracellular fluids (Plow and Miles, 1990). Taken together, 
these observations suggest plasmin generation and activity can be focused to 
restricted domains of the cellular environment, such as the leading edge of migrating 
cancer cells. 
In the fibrinolytic system, plasminogen is bound to a solid fibrin substrate on the 
thrombus in a specific interaction through the lysine binding sites, allowing plasmin 
to be formed in situ and thus to escape the inhibitory effect of circulating plasma 
inhibitors (such as: a2-antiplasmin and a2-macroglobulin). Interaction by plasma 
inhibitors depends on the same kringle interactions as are involved in fibrin or cell 
binding. Plasminogen has been shown to interact in vitro with the surfaces of 
numerous human cell lines including endothelial cells (Cesarman et al., 1994), 
monocytoid cells (Miles et al., 1991), neurons (Parkkinen et al., 1991) and tumour 
cells such as human breast cancer cells (Ranson et al., 1998), fibrosarcoma cells, 
osteosarcoma cells, leukemic cells and glioma cells (Plow et al., 1995). Additionally, 
the binding of plasminogen to the cell surface enhances the rate of plasminogen 
activation whilst affording protection of cell-localized plasmin from its specific 
plasma inhibitor, a2-antiplasmin (Ponting et al., 1992). 
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Binding of plasminogen to various cellular receptors is mediated by lysine binding 
site motifs found in the five triple disulfide-bonded loop structures known as kringles 
in its binding domain (also see section 1.2.2). Plasminogen interacts with cell surface 
proteinaceous and non-proteinaceous moieties (Miles et al., 1991). The binding of 
plasminogen to intact cell could be reduced when lysine analogues are present at the 
same time (Ranson et al., 1998). Although this does not completely inhibit the 
interaction, plasminogen characteristically binds to cells with low affinity (Kd range: 
0.1-2 |iM) in a lysine-dependent manner and with relatively large numbers of binding 
sites per cell (Plow and Miles, 1990). Thus the pericellular binding sites could provide 
a means of recruiting plasminogen for focalized extracellular proteolysis, and this cell 
surface localization of plasminogen would facilitate cell migration. To date, nine 
heterogeneous candidate cell surface plasminogen binding proteins have been 
identified and six other proteins remain essentially unidentified and uncharacterized 
(Plow et al., 1995). 
The activation of uPAR-bound sc-uPA has been found to occur much faster than 
unbound sc-uPA (Ellis et al., 1989; Duval-Jobe and Parmely, 1994). This indicates 
that uPAR may play an important role in regulation of uPA activation. Subsequently, 
the levels of uPAR have a major effect on the generation of plasmin and the ability of 
cells to degrade the surrounding ECM. Since GPI molecules have been known to 
relay intracellular signal transduction, it is possible that uPAR may also be involved in 
cellular signal transduction. uPAR not only binds uPA but is also a major binding 
protein of vitronectin in ECM, thus altering the cellular morphology and its adhesive 
properties (Kanse et al., 1996; Wei et al., 1996). 
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The role of uPA-uPAR complex in thrombosis and homeostasis is supported by severe 
thrombosis seen in plasminogen-deficient mice and in a high percentage of uPA 
'knock out' animals (Carmeliet et aL, 1994). A functional uPA-uPAR interaction is 
also required for tumour cell penetration of fibrin, activation of plasminogen and 
other proteases to breakdown ECM, which facilitate tumour growth and metastases 
(Bugge et aL, 1995). Elucidation of the role of uPA-uPAR in tumour progression over 
the last few years and its usefulness as a prognostic marker to follow disease 
progression has resulted in the establishment of uPA-uPAR as a potential target for 
anticancer therapy (see section 1.3 & 1.4 for detail). 
1.3 PLASMINOGEN ACTIVATION CASCADE SYSTEM AND HUMAN 
CANCER 
As described in section 1.1, during human cancer invasion and metastasis, malignant 
tumour cells cross extracellular biological barriers by attachment to and interaction 
with components of the ECM, and by local proteolysis. While the tPA activation 
system plays the key role in fibrinolysis, the uPA activation system is primarily 
involved in pericellular proteolysis. Strong experimental and clinical evidence has 
accumulated that the tumour-associated plasmin, uPA, uPAR, PAI-1 and PAI-2 are 
linked to cancer invasion and metastasis. 
1.3.1 The dynamic regulation of the plasminogen activation cascade system on 
the malignant cell surface 
As described above, the cell surface is the site of assemblage of a powerful urokinase 
plasminogen activation proteolytic system. Cell surface receptors of proteases, their 
inhibitors and specific interaction between proteases are tightly regulated in this 
system under physiological and pathological conditions. The general organization of 
this system on malignant cell surface is summarized in Fig. 1.6. 
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Figure 1.6 The general organization model of the malignant tumour cell 
surface urokinase plasminogen activation system. Pig, plasminogen. Pn, 
plasmin. After uPA-uPAR-PAIs complex internalization, uPA & PAIs 
degraded but uPAR recycled back to cell surface. 
As described in Fig. 1.5 and 1.6, penetrating malignant tumour cells focus proteolytic 
activity to the cell surface through receptors for plasminogen / plasmin and uPA. The 
uPAR on the tumour cell surface binds sc-uPA released from surrounding tumour cells 
and stroma cells (Ploug et al., 1991). This binding provides the malignant cells with a 
potential proteolytic activity at a specific point, and enhances the rate of the 
conversion from sc-uPA to active tc-uPA by a number of proteases including 
kallikrein, cathepsin and cell surface bound active plasmin. This binding may also 
induce cell adhesions and initiate a signal-transduction pathway via the GPI anchor of 
uPAR. Active tc-uPA catalyses activation of plasminogen to plasmin at the cell 
surface. 
The activation of receptor bound plasminogen to plasmin is enhanced as cell surface 
bound plasmin is protected from circulating inhibitors (e.g. a2-antiplasmin). Active 
cell surface bound plasmin can then directly or indirectly catalyze the degradation of 
ECM that facilitates malignant tumour cell proliferation, invasion and metastases (as 
described in section 1.1.2). ECM degradation activity of the system is regulated by the 
balances between levels of expression of components of the uPA system. High levels 
of specific inhibitors, such as PAI-1, PAI-2 and a2-antiplasmin, can down-regulate the 
ECM degradation activity of the system. While high levels of expression of uPA, 
uPAR and plasminogen will increase the ECM degradation activity. Proteolytic action 
of uPA is controlled by its inhibitors PAI-1 and PAI-2 which bind to the cell surface 
associated uPA-uPAR complex forming an enzymatically inactive receptor-protease-
inhibitor complex which is internalized by the tumour cells (Conesi and Blasi, 1995). 
It appears that the protease uPA and the inhibitor PAI-1 have to be present in the 
tumour to achieve effective uPAR mediated limited proteolysis. The internalization 
and recycling of uPAR may restore focalized cell surface-associated proteolytic 
activity (Fig. 1.6) (Liu et al., 1995). 
Expression levels of some components in the system, such as uPA, uPAR and PAI-1, 
are regulated by a large variety of hormones, growth factors and cytokines (reviewed 
by Besser et al., 1996). Oncogenic transformation of the cells may lead directly to an 
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increase in expression of some components of the uPA system (Duffy, 1993). 
Oncogenic transformation may also confer on cancer cells the ability to direct gene 
expression of neighbouring cells (Anderasen et al., 1997). This may explain the up-
regulation of certain components of the system (e.g. cancer cell surface uPA-uPAR 
complex) in some metastatic cancer cell lines. 
1.3.2 uPA / uPAR and cancer 
The uPA-uPAR interaction on cancer cell surfaces is a key event that results in 
increased in vitro matrix degradation and migration (Duffy, 1993). In prostate cancer 
cell lines, uPA was secreted in higher amounts in an invasive cell line as compared to 
a noninvasive cell line and was immunohistochemically localized to the leading edge 
of invasive cells (Gaylis et al., 1989). In human breast cancer cell lines, the metastatic 
cell line MDA-MB-231 showed higher cell surface expression of uPA-uPAR, 
significantly more cell surface bound plasminogen, and larger amount of plasmin 
generating than non-metastatic cell lines MCF-7 and T-47-D (Long and Rose, 1996; 
Ranson et al., 1998). Transfection of uPA or uPAR cDNA into the low uPA or uPAR 
expressing human osteosarcoma cell line was found to increase uPA or uPAR 
expression and enhanced its rate of ECM invasion (Kariko et al., 1993). Furthermore, 
uPA cDNA transfection of rat prostate carcinoma cells enhanced their metastatic 
potential in rats (Achbarou et al., 1994). Antibodies against uPA inhibited cell 
invasion in vitro models (dayman et al , 1993; Reich et al., 1988; Mignatti et al., 
1986;). In experimental animal models, antibodies against uPA inhibited tumour 
metastasis in the chick embryo (Ossowski, 1988), spontaneous metastasis in mice 
(Kobayashi et al., 1994), and local invasion in nude mice (Ossowski et al., 1991). 
Inhibition of uPA and / or uPAR expression by antisense sequence to uPA / uPAR 
mRNA have been found to reduce the invasive capacity of human fibroblast cell 
(Quattrone et aL, 1995). Also antisense uPA oligonucleotides reduced the spread of 
human ovarian cancer in mice (Wilhelm et aL, 1995). Synthetic uPA inhibitors 
reduced invasion and metastasis in a murine mammary tumour model (Alonso et aL, 
1996). 
All these findings from both in vitro and in vivo experiments suggested that cell 
surface over-expression of uPA and / or uPAR will lead to an increase in the 
metastatic capacity of the cancer cell lines. The clinical findings as to the extent of 
involvement of uPA in tumour cell invasion and metastasis supported these 
experimental studies. 
Altered expression of uPA has been found in almost all types of human cancer by a 
variety of techniques including cancer of the breast (Duffy et aL, 1988), prostate (Plas 
et aL, 1998; Kircheimer et aL, 1985), cervix (Camiolo et aL, 1987), endometrium 
(Bulletti et aL, 1991), ovary (Saito et aL, 1990), skin (Delbaldo et aL, 1994), colon 
(Sier et aL, 1994), stomach (Nekarda et aL, 1994), bladder (Gorelik et aL, 1990), 
kidney (Hofmann et aL, 1996), lung (Pedersen et aL, 1994), and leukemia (Wilson et 
aL, 1992). Measurement of uPA in extracts of tumours from patients was found to 
have prognostic significance for relapse in breast cancer (Foekens et aL, 1992; 1995), 
colorectal cancer (Ganesh et aL, 1994), gastric cancer (Nekarda et aL, 1994), and 
kidney cancer (Hofmann et aL, 1996). Similar to that already performed on uPA, 
uPAR was subjected to an intensive clinical analysis in cancer patients. It has been 
localized by in situ hybridization and immunohistochemistry in colon carcinoma 
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(Pyke et al., 1994), in breast (Bianchi et al., 1994) and skin cancer (de Vries et al., 
1994). Measurement of uPAR in tumour tissue extracts was of prognostic value in 
lung cancer (Pedersen et al., 1994-1) and renal cell carcinoma (Hofmann et al., 1996). 
A ligand-free, soluble form of uPAR was found in the ascites fluid of ovarian cancer 
patients (Pedersen et al., 1993). Therefore, these studies have shown that the levels of 
uPA and uPAR expression are significantly associated with the metastatic capacity of 
cancer cells. 
1.3.3 PAI-1 and cancer 
PAI-1 is the major plasminogen activator inhibitor in plasma and the endotheUum. 
Although it plays the key role in fibrinolysis by regulating tPA, PAI-1 can bind active 
tc-uPA and complex formation of uPA-uPAR-PAI-1 causes internalization and 
degradation of the complex (Cubellis et al., 1990). Paradoxically, PAI-1 may be 
directly involved in cancer progression, since tumour cells and capillary endothelial 
cells express higher levels of PAI-1 than other cell types (Heiss et al., 1995). Evidence 
from in situ and immunohistochemical studies support that PAI-1 was associated with 
cancer progression. PAI-1 was detected in endothelial cells in colon cancer (Pyke et 
al., 1991), was elevated in breast carcinoma tissue as compared to benign tissue 
(Reilly et al., 1992), was expressed in melanocytic neoplasia (Delbaldo et al., 1994), 
in liver cancer (Fitch et al., 1994), and immunohistochemically localized to primary 
tumour and metastases of Lewis lung carcinoma (Kristensen et al., 1990). 
PAI-I has been correlated with a poor prognosis for a variety of cancers including 
pulmonary carcinoma (Pedersen et al., 1994-2), stomach cancer (Nekarda et al.. 
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1994), and renal cell carcinoma (Hofmann et al., 1996). Furthermore, metastasis of 
ovarian cancer patients contained two fold more PAI-1 than the primary neoplasms 
(Schmalfeldt et al., 1995). In colorectal cancer, eightfold more PAI-1 was determined 
in liver metastases as compared with the primary tumour (Sier et al., 1994). Most 
interesting of all was the clinical finding that tumour associated PAI-1 was an 
independent and significant marker for recurrence in breast cancer (Foekens et al., 
1994). 
In vitro studies, using a variety of cancer cell lines or experimental manipulation of 
PAI-1 in cells, have given conflicting results. For example, Cajot et al. (1990) showed 
that PAI-1 inhibited an invasive phenotype when fibrosarcoma and colon carcinoma 
cells were transfected with PAI-1 cDNA, but Soff et al. (1995) showed that invasion 
was not inhibited in PAI-1 transfected prostate cells as compared to control cells (Soff 
et al., 1995). Matrix-bound PAI-1 inhibited the invasion of monocytes in vitro 
(Kirchheimer et al., 1990), capillary tube formation in vitro in a dose dependent 
manner (Schnaper et al., 1995), and tumour growth, angiogenesis and metastasis in 
animal models (Soff et al., 1995; Ma et al., 1997; Jankun et al., 1997). However, 
expression of PAI-1 along with uPA-uPAR facilitated optimum invasiveness of lung 
cancer cells (Liu et al , 1995). Most surprising of all was the result that host-produced 
PAI-1 is essential for cancer invasion and angiogenesis in a PAI-1 deficient (PAI-1') 
mouse model (Bajou et al., 1998). 
There is accumulating evidence that both uPAR and PAI-1 are multifunctional 
proteins involved not only in ECM proteolysis, but also in cellular adhesion and 
migration through their binding sites for vitronectin (Chapman et al., 1997). Due to 
these recent developments, a shift in thinking of the significance of PAI-1 in tumour 
pathogenesis has occurred. It has been suggested by Bajou et al. (1998) that 
expression of PAI-1 along with uPA-uPAR and plasminogen probably facilitates 
optimal cancer cell invasion and angiogenesis rather than unrestrained proteolysis. 
Their experimental result, that the bioavaliability of PAI-1 to endothelial cells is 
essential for capillary sprouting in tumour angiogenesis and as a consequence for 
tumour cell invasion, might explain the paradoxical relationship between PAI-1, high 
metastasis rate and poor survival in clinical findings. 
1.3.4 PAI-2 and cancer 
The exact role of PAI-2 in human cancer has not been explored deeply. To date most 
work in this area has focussed on PAI-1 with firm correlation between high levels of 
PAI-1, uPA and uPAR and a poor prognosis of cancer patients. However the exciting 
potential of PAI-2 as a suitable therapeutic or diagnostic agent is now being 
addressed. 
The recent availability of substantial amounts of human recombinant PAI-2 has 
allowed this serpin to be evaluated as a potential inhibitor of cell migration and 
tumour cell invasion (Kruithof et al., 1995). Exogenously added recombinant PAI-2 
inhibited the cancer cell plasminogen-dependent degradation of the subendothelial 
cell basement membrane (Baker et al., 1990). Also PAI-2 inhibited degradation by 
human melanoma cell M24met more effectively than tissue inhibitor of 
metalloproteinase type 2 (TIMP-2) (Montgomery et al., 1993). The role of PAI-2 was 
further studied using stably transfected HT-1080 sarcoma cell clones. Expression of 
recombinant PAI-2 in HT-1080 cells resulted in inhibition of ECM invasion in vitro 
and induction of a thick peritumoral capsule formation in vivo (Laug et al., 1993). In 
other animal models, human melanoma cells stably transfected with PAI-2 and 
injected subcutaneously (s.c.) in severe combined immunodeficient (SCID) mice had 
significantly less metastases in lung and lymph nodes than mock transfected control 
melanoma cells (Mueller et al., 1995). Intraperitoneal (i.p.) injection of PAI-2 resulted 
in a decrease of tumour mass after i.p. xenografting human A431 cells into nude mice, 
whereas the plasmin inhibitor tranexamic acid had no beneficial effect (Shinkfield et 
al., 1992). Daily intratumoral injection of PAI-2 into uPA producing DU-145 
subcutaneous tumours in SCID mice significantly decreased tumour size (Billstrom et 
al., 1994). 
Elevated levels of uPA, uPAR and PAI-1, but low levels of PAI-2 in primary tumour 
tissue clinically indicates poor prognosis, which mean shorter relapse free survival, 
shorter metastatic disease free survival, and a shorter overall survival of cancer 
patients (Duffy, 1996). A subgroup of breast cancer patients, characterized by high 
levels in tumour extracts of uPA and PAI-1 and low level of PAI-2 was identified, 
which had a very poor prognosis (Bouchet et al., 1994). 
All these results suggest that human recombinant PAI-2 has exciting potentiality to be 
used in a number of therapeutic applications for cancer. By virtue of its capacity to 
inhibit one of the key enzyme protease cascades (i.e. urokinase plasminogen 
activation cascade) responsible for ECM degradation and subsequent malignant 
cellular invasion and metastasis, PAI-2 could be used as a promising anti-metastatic 
agent in human cancer therapy. Pharmacokinetic studies investigating the potential 
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use of PAI-2 as a cancer therapeutic agent showed promising results (Hang et al. 
1998). Injection of labeled human recombinant PAI-2 into nude mice xenografted 
with the metastatic human colon cancer cell HCT-116 resulted in accumulation of 
PAI-2 in the primary tumour with relatively rapid clearance from other organs. PAI-2 
binding to HCT-116 cells in vitro could be blocked by specific inhibitors of uPA 
activity and anti-uPA antibodies, indicating that localization to the primary tumour in 
vivo may block uPA dependent proteolysis (Hang et al., 1998). This localization and 
accumulation of PAI-2 in tumour tissues strongly argues for the potential therapeutic 
use of PAI-2 in human cancer (further discussed in section 1.4). 
1.4 TARGETED THERAPY AND HUMAN CANCER 
1.4.1 Overview 
Despite recent advances in characterizing the cell biological and molecular basis of 
human cancers, their early detection with the aid of new imaging and diagnostic 
techniques, and multiple traditional therapies, the mortality from most human cancers 
is still high. The most important problem in the management of cancer is control of 
metastatic disease. Traditional human cancer therapies, including surgery, 
chemotherapy and radiotherapy, are unable to control the distant metastasis due to 
incompletely killing of invisible malignant tumour cells that have spread all over the 
body in the later stage of cancers (Allen, 1999). An approach that has not been fully 
developed to date that may overcome this problem is named "Targeted Therapy". 
Targeted therapy, first developed at the turn of 20'^ century by Paul Erhilch, is based 
on the idea that a drug will attack its target without damaging any other tissues (from 
Raso V, 1990). Erhilch referred to the targeting drug as a "magic bullet" that must 
contain a cancer localizing and medicament moiety. The medicament moiety could be 
a toxin, drug or radionuclide that causes cell death. If by this idea the cytostatic 
compound is specifically localized to malignant tumour cells but not normal cells, e.g. 
haemopoietic cells of the bone marrow, the efficacy of human cancer management 
could be substantially increased. 
Since antibodies can specifically bind with high affinity to tumour associated antigens 
on malignant cell surfaces, it is not surprising that antibody-medicament conjugates 
were and are considered a way to increase the selectivity of cancer therapy. So far 
most monoclonal antibodies applied in immunoconjugate research and clinical 
applications are of murine origin due to difficulties in producing human antibodies of 
a desired specificity and large quantities (James, 1990; Philip et al., 1997). This leads 
to negative immunogenic side-effects from allergic reactions to anaphylactic shock in 
some patients (Raso, 1990). Most seriously, patients who were not severely 
immunosuppressed produced antibodies that bound to and neutralized the injected 
murine monoclonal antibodies, thus making further therapy with the antibody 
pointless (Philip et al., 1997). 
In addition to the immunogenic reactions of murine monoclonal antibodies in humans, 
other problems undermined the therapeutic value of the antibodies in anticancer 
clinical trials. For example, the emergence of antigen-negative mutation on tumour 
cells has limited the use of monoclonal antibodies. Anti-idiotype antibodies alone or 
in combination with interferon-a produced only 15-25% complete remissions in 
phase III clinical trials in "follicular lymphoma" patients. Most other patients had 
marked temporary remissions curtailed by the emergence of idiotype-negative mutant 
lymphoma cells as was seen in previous animal studies (Philip et al., 1997). Another 
obstacle was the phenomenon of antigenic modulation on cancer cells. Most drug or 
toxin conjugates act only within the cell. However internalization of cell surface-
attached antibodies does not necessarily happen in every case. Some cell surface 
antigens, when cross-linked by antibodies, are shed from the cell surface (Philip et al., 
1997). This reduces the number of molecules of target antigen available for binding 
by the antibody-medicament conjugates, and may allow the cell to escape killing as 
the modulated antigen is re-expressed only when antibody is no longer present some 
days later (Raso V, 1990; Philip et al., 1997). Furthermore, the effectiveness of the 
antibody treatment was reduced by the formation of complexes between the infused 
antibody and target antigens shed from the tumour cell surface. To date there is no 
good solution to the problem of antigen shedding (Philip et al., 1997). Altogether, 
these drawbacks of antibody treatments suggest that an alternative approach to 
discriminating between malignant and normal cells in targeted anticancer therapy may 
yield better results. 
Three major steps should be considered in contemplating an ideal targeted therapeutic 
modality. The first is to find and select a stable cancer marker (cell surface associated) 
present in the human cancer to be targeted. The second step is to provide a special and 
high affinity-binding component as a device to carry the cell-killing medicament and 
bind the cell surface marker. Finally it is necessary to produce a suitable carrier-
medicament conjugate to effectively kill the targeted cancer cells and spare critical 
normal cells. 
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The most important consideration in the selection of a cancer marker is the number of 
cancer cell types that express or overexpress it. It is very difficult to find one special 
marker that is expressed by all cells in all kinds of human cancers. As discussed in 
section 1.3, strong experimental and clinical evidence indicate that components of 
plasminogen activation system: plasmin, uPA, uPAR and the inhibitor PAI-1 are 
associated with many human cancers invasion and metastasis. Therefore, it seems 
obvious that one or all of these components could be useful targeting markers in many 
human cancer types. 
1.4.2 Receptors bound uPA as a human cancer cell target: use of PAI-2 as a 
targeting device 
As described in section 1.3.2, uPA and / or uPAR are overexpressed on many human 
cancer cells surface when compared with normal cells. Thus uPA and / or uPA/uPAR 
complex could be targeted as a marker in anticancer therapy, using a ligand (amino 
terminal fragment of uPA to target receptor) or polyclonal and monoclonal antibodies. 
However utilization of these tumour localizing factors as target devices do not secure 
internalization of conjugated cell-killing medicament, do not overcome the problems 
of cancer cell surface antigen-negative mutation and antigenic modulation, and do not 
overcome the negative immunogenic side effects of murine origin antibodies as 
discussed in section 1.4.1. 
Another promising method of delivering the medicament to cancer cells is to 
conjugate medicament with human natural inhibitors of uPA: PAI-1 or PAI-2. Since 
PAIs do not target specific cancer (like most antibody strategies), they could 
potentially be used against a wide range of malignant human cancers wherever 
cellular uPA overexpression is thought to play crucial roles in invasion and metastasis. 
As proteins of human origin, PAIs are not immunogenic and therefore superior to 
murine origin antibodies proposed for targeted human cancer therapy. PAIs 
specifically bind to uPA/uPAR overexpressed on the surface of malignant cancer cells 
with high affinity, after binding PAIs trigger internalization of the uPA-uPAR-PAIs 
complex into the cancer cells (Cubellis et al., 1990; Jensen et al., 1990; Hang et al., 
1998; also see review in Kruithof et al., 1995; and review in Carroll and Binder, 
1999). Thus, if a suitable lethal medicament is conjugated to PAIs, the uPA-uPAR-
PAIs-medicament complex would localize to and be internalized into the targeted 
cancer cells. After internalization, the complex is degraded, the receptors are recycled 
(Nykjaer et al., 1997; also see review in Carroll and Binder, 1999), the product of 
protein degradation and the medicament are released to the cytosol which secure and 
increase the efficacy of medicament killing ability (Fig. 1.7). 
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Figure 1.7 Model of the 'Magic bullet' in targeted anti-cancer therapy. Receptor-
bound uPA (uPA/uPAR) as a human cancer cell target. PAIs as a targeting device 
carrying lethal medicament to kill the targeted cancer cells. 
Although PAI-1 has been studied more extensively than PAI-2, unfortunately PAI-1 is 
not a stable protein, as it spontaneously converts itself into a latent, inactive form 
(Pollanen et aL, 1991). The latent form of PAI-1 does not possess the ability to bind 
uPA and is therefore useless in targeted anticancer therapies (see section 1.2.4.2 for 
detail). However, the modification of PAI-1 to prevent its conversion into the inactive 
form has been tried. Jankun (1994) reported 4-succinimidyloxycarbonyl-a-methyl-a-
(2-pyridyldithio)-toluene (SMPT) modified PAI-1 conjugated with saporin in in vitro 
cell-killing assays of the high uPA expressing HT1080 fibrosarcoma cell line and in in 
vivo antitumour assays in HT1080 xenografted SCID mice. Results demonstrated the 
effectiveness of PAI-1 in recognizing cancer cells and delivering the cytotoxic 
compound into the cancer cells as a targeting device. But they found that both PAI-1 
was heavy modified by SMPT. Furthermore, conjugation of SMPT-PAI-1 with 
saporin also had serious negative effects on the activity of PAI-1 (Jankun, 1994). 
On the other hand, PAI-2 has several distinct advantages compared with PAI-1. First 
of all, PAI-2 is a stable protein, whereas PAI-1 is unstable and more sensitive to 
oxidation (see section 1.2.4). Furthermore, in pregnant women sustained elevated 
PAI-2 levels (at least up to 300 ng/ml) appear to have no systemic or pathologic 
consequences (Kruithof et al., 1987), whereas sustained elevations of PAI-1 may be 
thrombogenic (Erickson et al., 1990). Also PAI-2 is 10,000-fold less active toward sc-
tPA than PAI-1, which allows for a larger window of efficient uPA inhibition (see 
section 1.2.4). Finally, as mentioned in section 1.3.4 the localization and accumulation 
of PAI-2 in tumour has been demonstrated in Hang (1998). Furthermore high doses of 
Î ^̂  labeled PAI-2 (up to 500 ng/mouse) into these mice did not cause any side effects 
(Hang et al., 1998). Thus the potential therapeutic value of PAI-2 in targeted 
anticancer therapies is promising and demands further study. 
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1.4.3 Animal model and targeted anti-cancer therapy 
The preclinical experiments in targeted anticancer therapy need good in vivo animal 
models that can mimic the natural history of human cancer invasion and metastasis. 
By systemically introducing suitable targeting device-medicament conjugates into 
these in vivo human cancer xenografted animal models, the efficacy of novel targeted 
anti-cancer therapies before clinical trial in human beings may be assessed. 
A major limitation of in vivo models for this study is the lack of the many host factors 
that participate in the physiological and pathological mechanisms contributing to the 
malignant phenotype. Only a few experimental models are available for in vivo 
investigations of human cancer cell invasion and metastasis (Dagg et al., 1956; 
Kozlowski et al., 1984). One suitable model for this study is the athymic nude mouse 
(Fidler, 1986; Neulat-Duga et al., 1980). Most studies in this nude mouse model have 
been based on injections of tumour cells intravenously, and this approach involves 
only the later steps of the metastatic process. A subcutaneously inoculated or serially 
transplanted tumour demonstrating local invasion and spontaneous metastatic spread 
is a more adequate model for the invasive and metastatic behaviour of cancer cells. 
However, there not only has been Umited success in establishing human tumour cell 
lines that reproducibly spread in nude mice after subcutaneous inoculation, difficulties 
in identifying small metastases throughout the mouse have also been a very 
significant problem (Ossowski and Reich, 1980). A number of human melanoma cell 
lines have been found to metastasise in nude mice, and the expression of melanin m 
some of these melanoma cell lines facilitated the identification of metastasis in the 
nude mice (Ishikawa et al., 1988). Unfortunately, melanin production is restricted to 
certain malignancies, and therefore can not be used as a general marker for the 
identification of human cancer cells in the nude mouse (Wilson et al., 1988). 
Recently, Farina et al. (1998) developed a model that directly examines the motility of 
metastatic primary tumour cells in situ. This is the first time that living primary 
tumour cells in a live animal have been visualized as part of a chnically relevant 
model. A metastatic rat breast cancer cell line MTLn3+GFP was established by green 
fluorescent protein (GFP) gene transduction that constitutively expresses green 
fluorescent protein in primary and metastatic tumours throughout the life span of the 
animals injected. The fluorescent primary and metastatic tumours appear much 
brighter than the background of host tissue under the light passed through an FITC 
filter set. GFP expression in tumours was also confirmed by inmiunohistochemistry 
with an anti-GFP polyclonal antibody. Animations of a single metastatic tumour cell 
moving in live animals were generated by intravital imaging of the primary tumour in 
situ on a laser scanning confocal microscope (Farina et al., 1998). Further 
development of this interesting experiment may provide a novel method to access 
human cancer invasion and metastasis in animal models. 
1.5 AIMS 
The overall aim of this project was to assess the viability of using PAI-2 as a targeting 
device in future human targeted anti-cancer therapy projects. 
The specific aims of this project were: 
• To confirm and determine the expression level of cell surface bound uPA of 
human breast cancer cell lines HS-578-T, MDA-MB-231, MCF-7 and human 
prostate cancer cell line PCS by flow cytometry. 
• To determine the cell surface expression level of endogenous PAI-2 of HS-578-T, 
MDA-MB-231 and MCF-7; and exogenous PAI-2 binding of metastatic cell lines 
HS-578-T and MDA-MB-231 by flow cytometry. 
• To produce stable transfection of M D A - M B - 2 3 1 with green fluorescent protein 
(GFP) cDNA; and to check expression levels of uPA and GFP on transfected 
M D A - M B - 2 3 1 - h G F P cell surface. 
• To perform preliminary confocal microscopy to examine exogenous PAI-2 
internalization by MDA-MB-231+GFP cells. 
• To develop in vivo breast cancer models by subcutaneous inoculation of MDA-
MB-231 and MDA-MB-231+GFP cells into mammary fat pads of nude mice. 
2. MATERIAL AND METHODS 
2.1 Cell culture 
The human breast cancer cell hnes in this study (MDA-MB-231, MCF-7, HS-578-T) 
and the human prostate cancer cell line PCS were all routinely cultured in RPMI-1640 
supplemented with 10% (v/v) heat-inactivated fetal calf serum (PCS). The cells were 
all incubated in a humidified incubator at 37^C with a 5% carbon dioxide: 95% air 
atmosphere. 
Human breast cancer cell lines (MDA-MB-231, MCF-7, HS-578-T) were from 
American Tissue Culture Collection (ATCC), USA. Human prostate cancer cell line 
PC3 was a gift from Professor Barry J Allen (St George Hospital Cancer Care Center, 
Kogarah, NSW, Australia). RPMI-1640 was purchased from Trace Biosciences 
(Castle Hill, NSW, Australia). PCS was obtained from CSL (Parkville, Victoria, 
Australia). 
2.2 Preparation of pEGFP-Nl for transfection of MDA-MB-231 cells 
Green fluorescent protein (GPP) reporter gene was used in this study to produce a 
heritable, stable volume marker of metastatic human breast cancer cell line MDA-
MB-231 that allows cells to be followed in the process of invasion and metastasis 
after being xenografted into nude mice in the long term. The GPP gene has been 
cloned in the mammalian expression N-terminal protein fusion vector pEGFP-Nl in 
DH5a bacteria (purchased from CLONTECH, Palo Alto, CA, USA). The pEGFP-Nl 
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vector contains a number of features including Pcmv, GFP reporter gene, selectable 
marker NEO^ (neomycin resistance), and multiple cloning sites. 
Single colonies of DH5a bacteria containing pEGFP-Nl were inoculated in 100ml LB 
broth supplemented with 50 |ig/ml kanamycin, and grown overnight at 37°C with 
shaking. The plasmid DNA was extracted and purified by Qiagen Plasmid Midi kit 
(purchased from Qiagen, Pty Ltd., Clifton Hill, Victoria, Australia), following the 
manufacturer's instruction, and stored at -20°C for later transfection of the human 
breast cancer cell line MDA-MB-231. The yield and purification were determined by 
U. V. spectrophotometry at 260 and 280 nm. Linearised pEGFP-Nl was produced by 
digesting uncut supercoiled pEGFP-Nl DNA (~2 |Lig) samples with 1 jil Bgl 11 
restriction endonuclease (Boehringer Mannheim Biochemica), 2 jil lOx incubation 
buffer M (Boehringer Mannheim Biochemica), and 14 |il dH20 in a final 20 |LL1 
volume at 37^C overnight. The original extracted DNA and the digestion sample were 
examined by electrophoresis on 1% agarose in Ix TAE buffer at 60 V over 1 hour. 
2.3 Stable transfection of adherent MDA-MB-231 cells with pEGFP-Nl plasmids 
The adherent MDA-MB-231 cells were transfected with the linearised pEGFP-Nl 
plasmid (-Ijig) using the SuperFect Transfection Reagent (STR) kit (purchased from 
Qiagen Pty Ltd., Clifton Hill, Victoria, Australia). The experiment was carried out as 
recommended by the protocol of the STR kit. The general principle of STR is that the 
reagent is a specifically designed activated dendrimer that can form a complex with 
DNA upon incubation at room temperature (20-25°C). The STR-DNA complexes 
possess a net positive charge, which allows them to bind to the negatively charged 
receptors (e.g. sialylated glycoproteins) on the surface of MDA-MB-231 cells in this 
case. The STR-DNA complexes are then taken into the cells by endocytosis process 
(Fig.2.1). 
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Figure 2.1 The general principal of the SuperFect Transfection Reagent (STR) in 
stable transfection of MDA-MB-231 cells with pEGFP-Nl plasmid. 
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The efficiency of transfection of different cell lines with STR is dependent on a 
number of parameters. Therefore, it is necessary to optimize these parameters to yield 
high levels of transfection. Stable transfection of MDA-MB-231 was carried out to 
optimize the ratio of the amount of STR to the amount of pEGFP-Nl DNA. This ratio 
will determine the net charge of the STR-DNA complexes, which allows the 
complexes to bind to the cell surface and to be taken up by the cells. As a sequence, 
this ratio will determine the efficiency of transfection of the MDA-MB-231 cell line. 
The optimization of the efficiency of the stable transfection experiment was 
performed by following the STR kit (Qiagen) manufacturer's instructions as shown in 
Table 2.1. 
Table 2.1 Ratio of SuperFect Transfection Reagent (STR) to pEGFP-Nl DNA for 
optimizing the efficiency of stable transfection of MDA-MB-231 cells (modified 
from Qiagen manufacture's instructions). 
Ratio of STR to DNA 
0:1 2:1 4:1 6:1 8:1 10:1 4:0 
Amount of DNA (̂ ig) 1 1 1 1 1 1 0 
Amount of STR (|il) 0 2 4 6 8 10 4 
The entire stable transfection of MDA-MB-231 with pEGFP-NlDNA procedure was 
carried out under sterile conditions. The MDA-MB-231 cells were grown in RPMI-
1640/10% FCS in a 24-well plate until the cell culture reached 20-40% confluence 
(about 48 hours) on the day of transfection. This was to ensure that the cells were at 
the optimal phase of growth and in order to increase the efficiency of the expression 
of the GFP gene. 
An appropriate amount of purified pEGFP-Nl DNA (8 jig) was diluted with RPMI-
1640 (containing no serum and antibiotic) to a final volume of 150 |il. The sample 
was mixed and aliquots containing 1 jig DNA were mixed with different volumes of 
SuperFect Transfection Reagent as indicated in Table 2.1. The samples incubated at 
room temperature (20-25°C) for 10 minutes, allowing the STR-DNA complexes to 
form. 
While the complex formation took place, each well of MDA-MB-231 cells was gently 
washed once with 1 ml of sterile PBS. After the complex formation period, 1 ml of 
RPMI-1640/10% FCS with 0.8 mg/ml active antibiotic Geneticin (purchased from 
Life Technologies, Inc. Grand Island, NY, USA) was added into each reaction tube 
containing the transfection STR-DNA complexes. The sample in each reaction tube 
was mixed gently as before and immediately transferred to the different wells of 
MDA-MB-231 cells in 24-well plate. The transfection complexes were incubated with 
the cells for 3 hours in a humidified incubator at 37^C with a 5% carbon dioxide: 95% 
air atmosphere. After the incubation period, the transfection solution was removed 
from the cells by very gentle aspiration. Each well of cells was washed 4 times with 1 
ml of sterile PBS. Finally 1 ml of fresh medium RPMI-1640/10%FCS was added into 
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each well. 
The transfected MDA-MB-231 cells were evaluated for GFP fluorescence after 48 
hours and 72 hours under the fluorescence microscope. Cells that had successfully 
integrated the pEGFP-Nl DNA into their chromosomes were routinely cultured in 
RPMI-1640/10%FCS supplemented with final concentration 0.4 mg/ml active 
Geneticin (G-418 Sulfate) as a selective agent. Only successfully transfected MDA-
MB-231 cells survived and divided. 
After several weeks in culture, sufficient numbers of GFP expression MDA-MB-231 
cells were obtained. The presence of GFP fluorescence in these cells was detected by 
flow cytometry (Becton-Dickinson) using FL-1 detector (green fluorescent detector), 
and photographed using a fluorescence microscope. 
Highly GFP expressing MDA-MB-231+GFP cells were selected by fluorescence activated cell 
sorting using flow cytometry (FACSort, Becton-Dickinson). Cells were cloned three times by 
limiting dilution method. This involved placing 100 |il of cells (1x10^ /ml) into Al 
well of the 96-well plate. A decade dilution down the first column of the plate was 
performed, and followed by a decade dilution of this column of cells across the plate. 
This dilution resulted in several wells containing 1 or no cells. The plate was 
incubated until a single colony of GFP expression cells was observed under the 
fluorescence microscope. Cells from this colony were used for subsequent serial 
dilution. After third cloning step, cells were expanded and frozen down. The GFP 
fluorescence of viable normal MDA-MB-231, before, and after sorting and cloning 
MDA-MB-231+GFP cells was analyzed by dual colour flow cytometry (Becton-
Dickinson). All data were then analyzed by using CELLQuest software (Becton-
Dickinson). 
2.4 Characterization of breast cancer cell lines and prostate cancer cell line by 
flow cytometry 
In this study, the expression levels of cell surface uPA and endogenous PAI-2 of 
viable MDA-MB-231 and HS-578-T, and MCF-7 cell lines were determined by 
indirect immunofluorescence staining with FITC (a green fluorescent label). The 
expression level of cell surface uPA of human prostate cancer cell line PCS was 
determined by using the same technique. 
All immunofluorescence labeling in these experiments was detected by dual-colour 
flow cytometry (Becton-Dickinson, USA), using FITC and propidium iodide (PI) 
fluorescence (as described in Ranson et al., 1998). The use of PI was to select only 
viable cells for analysis. PI (an orange fluorescent label) intensity was measured using 
the FL-2 detector of the flow cytometer. The viable FITC-labeled cells exclude PI and 
dead cells can be 'gated out'. Only viable cells were selected for data analysis (Fig. 
2.2). All data were analyzed using CELLQuest software (Becton-Dickinson). 
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Figure 2.2 A diagrammatic representation of dual-colour flow cytometric 
analyses used in this study. Dual-colour flow cytometry was used to detect 
two different characteristics of the cells at the same time, using two different 
fluorescent labels. The indirect or direct immunofluorescence labeling with 
FITC (a green fluorescein) was used to determine the cell surface uPA and 
PAI-2, while viable cells excluded dye propidium iodide (PI, an orange 
fluorescent label). Only cells that excluded PI were selected as viable cells 
for analysis. FITC fluorescence intensity was measured by FL-1 detector, 
while, PI intensity was measured by FL-2 detector of flow cytometer. 
Cells were firstly washed by PBS twice, then detached (after 48 hours of routinely 
culturing) with PBS / 5nilVI EDTA, incubating at room temperature (20-25^C) for 3-4 
minutes. Cells were washed and collected by centrifuging at 200g with ice-cold (4°C) 
Hanks / 0.1% BSA (pH 7.5) at a final concentration of approximately 1x10^ cells / ml. 
A sample of approximately 1x10^ cells was incubated with either mouse anti-human 
uPA monoclonal antibody IgG #394 (American diagnostica Inc, Greenwich, CT, 
USA, final concentration of 10 |ig/ml) or mouse anti-human PAI-2 (both 60 KDa and 
46 KDa forms) monoclonal antibody IgG #3750 (American diagnostica Inc, 
Greenwich, CT, USA, final concentration of 10 |Lig/ml) in 100 |il of ice cold Hanks / 
0.1% BSA on ice for 30 minutes. In the case of isotype control, the same final 
concentration of mouse anti-dinitrophenol IgG antibody DNP-P #399 (American 
Diagnostica Inc, Greenwich, CT, USA) was added instead of the mouse anti-human 
uPA or PAI-2 antibody. After incubation, cells were washed with 1 ml of ice cold 
Hanks / 0.1% BSA twice then incubated with 1: 100 dilution of FITC conjugated anti-
mouse IgG polyclonal antibody (Silenus, Sydney, NSW, Australia) in final 100 |il of 
ice cold Hanks / 0.1% BSA for 30 minutes on ice and in the dark to prevent 
photobleaching. Finally the cells were washed with Hanks / 0.1% BSA twice, and 
resuspended in 500 [L\ of ice cold PBS/0.1% sodium azide containing 5 |ig/ml of 
propidium iodide (PI). Immunofluorescence labeling was detected immediately by 
dual colour flow cytometry using CELLQuest software (Becton-Dickinson). 
In the case of transfected MDA-MB-231+GFP, PE (an orange fluorescent label) 
conjugated anti-mouse IgG polyclonal antibodies (Silenus, Sydney, NSW, Australia) 
was used because green fluorescence protein expression influenced the detectmg of 
FITC fluorescence. PI could not used to select viable cells due to the fact that only 
dual colour flow cytometry could be used successfully in this study. 
Recombinant human PAI-2 (47 KDa) was obtained from Biotech Australia Pty Ltd., 
Sydney, Australia. PAI-2 was conjugated with FITC and TRITC as described by 
Coding (1976). Unconjugated FITC or TRITC were separated by a PD-10 gel 
filtration column equilibrated with PBS/0.1% azide. The concentration of FITC- or 
TRITC conjugated PAI-2 was measured by Bio-Rad DC protein assay reagent kit 
(Bio-Rad Pty Ltd. Australia) following the manufacturer's instruction. The binding 
activities of FITC or TRITC conjugated PAI-2 were examined by their ability to form 
complexes after 30 minutes incubation with equimolar amounts of active human uPA 
(Serono, Sydney, NSW, Australia) at room temperature. The complex formation was 
detected by SDS-PAGE (12% non-reducing gel, all reagents for SDS-PAGE from 
Bio-Rad Pty Ltd. Australia). TRITC conjugated PAI-2 was used in the confocal 
microscope experiments (refer to section 3.6). 
Cells were harvested as above and resuspended in ice-cold (4°C) Hanks / 0.1% BSA 
(pH 7.5) at 2x10^ cells / ml. Then samples of approximately 2x10^ cells were pre-
incubated with or without plasminogen (20 |ig/ml) for 20 minutes at room 
temperature as pre-activated or non-activated groups. After washing with ice-cold 
Hanks / 0.1% BSA twice, the cells were incubated with FITC-PAI-2 for varying time 
(from 0 to 16 hours) at a final concentration of 10 \ig/m on ice in the dark. The cells 
were washed, and cell surface binding PAI-2 was detected by dual colour flow 
cytometry. In some cases cells were fixed after pre-activation with plasminogen in 1% 
paraformadenyde / PBS over 1 hour at room temperature, prior to FITC-PAI-2 
binding experiments as indicated. All data were analyzed by using CELLQuest 
software (Becton-Dickinson). 
2.5 Examination of exogenous PAI-2 binding and internalization in MDA-MB-
231+GFP cells by confocal microscopy 
Before final sorting and cloning, MDA-MB-231+GFP cells were used in a 
preliminary experiment to determine exogenous PAI-2 binding and internalization 
capacities using confocal microscopy (Leica DM IRB, with Leica TCS confocal 
system (Fig. 2.3). 
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Figure 2.3 A model of Leica DM IRB confocal microscope with Leica TCS 
confocal system (Leica Microsystems, Wetzlar Gmbh). 
Confocal microscopy detects structures by collecting light from a single focal plane of 
the sample, excluding light that is out of focus. In a point scanning confocal system, 
the microscope lenses focus the laser light on one point in the specimen at a time (the 
focal point). The laser moves rapidly from point to point to produce the scanned 
image. Both fluorescent and reflected light from the sample pass back through the 
objective. The microscope and the optics of the scanner module focus the fluorescent 
light emitted from the focal point to a second point, called the confocal point. The 
pinhole aperture, located at the confocal point, allows light from the focal point to 
pass through the detector. Light emitted from outside the focal point is rejected by the 
aperture (Fig.2.4). 
Oetectof 
Figure 2.4 The epi-illumination imaging mode of confocal 
microscopy. ' ' indicates object in focal plane. ' indicates 
object not in focal plane. 
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Cells were cultured on the top of round glass slide covers in a 24-well plate with 
RPMI-1640/10%FCS medium until they reached 40%-60% confluence (about 48 
hours). The cells in each well were very gently washed with 1 ml of Hanks /1% BSA 
twice, and pre-incubated with or without 20 |xg/ml plasminogen for 20 minutes at 
room temperature as pre- or non-plasminogen activated cell samples. Then samples of 
approximately 2x10^ cells were incubated with 200 |il Hanks / 1% BSA containing a 
final concentration 10 |ig/ml TRITC-PAI-2 in the dark. The fluorescence present the 
on cell surface or in the cytosol was detected by confocal microscopy at different time 
points. All data were analysed by Leica TCS software in Leica TCS confocal system. 
2.6 Human breast cancer in vivo nude mice model 
In this study, 4 and 6-week-old female Arc(s) nu/nu nude mice were purchased from 
Animal resources Center, Canning Vale, WA, Australia. Throughout all experiments, 
mice were maintained in a laminar flow cabinet under specific-pathogen-free 
conditions and monitored regularly in accordance with the Animal Ethics Conmiittee 
of the University of Wollongong (AE 96/07). 
Human breast cancer cells MDA-MB-231 and MDA-MB-231+GFP were routinely 
cultured in sterile RPMI-1640/10%FCS medium and tested free from mycoplasma 
contamination by PCR technology at Department of Microbiology, Westmead 
Hospital (Sydney) before xenografting. Under sterile conditions, cells were harvested 
with sterile PBS/EDTA, washed and resuspended with serum-free RPMI-1640 
medium at a final concentration of 2x10^ cells/ml. Xenografts of human breast cancer 
cells were induced by subcutaneous inoculation of 2 x lO^cells into the first pair of 
mammary fat pads on the 4- or 6-week-old nude mice thoracic wall. The mice were 
sacrificed when the tumours were bigger than 1.0 cm in diameters or at 8 weeks from 
the initial inoculation. The samples of tumour and major organs were stored in 10% 
formalin solution for future histopathological assays. Dissecting images of mice, 
tumours, tumour angiogenesis phenomenon and metastatic lymph nodes were 
captured by video camera and analysed using a Power PC (Macintosh 8500/20) 
computer with Apple Video Player software (Macintosh). 
3. RESULTS 
3.1 Determination of pEGFP-Nl DNA purification yield 
The pEGFP-Nl DNA was successfully extracted and purified from DH5a bacteria 
using Qiagen Plasmid Midi kit as determined by BLUE spectrophotometry (range of 
A260nm/A280nm' 1.8-2.0). The extracted pEGFP-Nl was an uncut supercoiled form (3.5 
Kb in size). Digestion of a sample of this original pEGFP-Nl with restriction 
endonuclease Bgl 11 is predict to produce a linearised pEGFP-Nl (4.7 Kb in size). 
Bands of 3.5 Kb and 4.7 Kb which corresponded to the exact size of supercoiled and 
linearised pEGFP-Nl respectively were observed, confirming that the extracted DNA 
was that of pEGFP-Nl (Fig. 3.1). 
Restriction linearised pEGFP-Nl (4.7 Kb) 
Uncut supercoiled pEGFP-Nl (3.5 
Kb) 
Figure 3.1 Electrophoresis result of uncut and restriction pEGFP-Nl 
examining. Lane 1 contained the 1 Kb ladder DNA marker. Lane 2 contamed 
a sample of uncut pEGFP-Nl. Lane 3 contained a sample of pEGFP-Nl 
digested with Bgl 11. 
3.2 Stable transfection of adherent MDA-MB-231 cells with pEGFP-Nl plasmids 
The best result of stable transfection with pEGFP-Nl was obtained with the ratio of 4 
|ll SuperFect Transfection Reagent to 1 |ig pEGFP-Nl DNA. Transfected cells 
obtained using the other ratios gradually died after culturing with Geneticin (0.4 
mg/ml). 
After cell sorting by flow cytometry, only the highest GFP expressing cells were 
selected by incubation with the antibiotic Geneticin as described above. Cloning of a 
single cell was attempted. Then a single colony originating from one single highest 
GFP expression cell was selected and cultured. A new clone MDA-MB-231+GFP, 
which had heterogeneous GFP expression due to either incomplete cloning or variable 
expression at different stages of cell cycle, was obtained and maintained. Without 
further Geneticin selection, this clone stably kept high GFP expression for at least 13 
passages. The MDA-MB-231+GFP cells were photographed at the passage under 
the fluorescence microscope (Fig. 3.2). The MDA-MB-23H-GFP cells were 
compared with untransfected or unsorted but transfected MDA-MB-231 cells by dual-
colour flow cytometry (Fig. 3.3 and 3.4). 
Figure 3.2 shows that almost all MDA-MB-231+GFP cells seen under the normal 
light source expressed green fluorescence under blue light stimulation, which 
confirmed the positive results of GFP gene transfection in this study. The cells marked 
with GFP were easily and clearly detected under blue light source microscopy. 
Figure 3.3 shows the density plots of FITC intensity vs PI intensity of (A) the 
untransfected normal MDA-MB-231 cells, (B) the mixed population of transfected 
MDA-MB-231 cells with low or high different GFP expression prior to cell sorting 
and cloning, and (C) the population of MDA-MB-231+GFP cells. The viability of the 
cells was assessed by the PI intensity. Non-viable cells were more permeable and able 
to uptake PI giving a bright orange fluorescence, whereas, viable cells were not 
permeable and were able to exclude PL The viable cells were gated in density plots 
and analyzed for FITC intensity in histogram plots (Figure 3.3 and 3.4). As shown in 
Figure 3.4 untransfected normal MDA-MB-231 cells had a very low level of FITC 
intensity that indicated these cells have a very low FITC-autofluorescence activity 
(2.3 ± 0.2 fluorescence units, n=3) and no GFP expression. Before cell sorting and 
cloning, there were two populations of transfected cells with very different levels of 
FITC intensity, which indicated one part of these transfected cells had a high GFP 
expression (1180 ± 40 fluorescence units, n=3), while another one had a low GFP 
expression (4.7 ± 0.4 fluorescence units, n=3). After cell sorting and cloning, one 
population of high GFP expression cells (MDA-MB-231-GFP) was found (1210 ± 60 
fluorescence units, n=3). This population of cells maintained high GFP expression 
after 13'̂  passages in the absence of Geneticin, indicating that the GFP gene was 
stably maintained on the genome of these cells. This new cell line MDA-MB-
231+GFP could therefore be used in the future for in vivo experiments as an easily 
monitored human breast cancer cell line. 
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Figure 3.2 Stably transfected MDA-MB-231+GFP cells under normal 
light and blue light source of fluorescence microscope. A) cells under 
normal light source (x 100 times). B) same cells as A under blue light 
source (x 600 times). C) cells under normal light source (x 100 times). D) 
same cells as C under U. V. light source (x 600 times). The MDA-MB-
231-GFP cells have heterogeneous GFP expression due to different stages 
of cell cycle. 
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Figure 3.3 Density plots showing green fluorescent protein (GFP) expression of 
MDA (normal MDA-MB-231) cells and MDA+GFP (stable transfected MDA-MB-
231+GFP) cells. All cell samples were resuspended in buffer with 5 |ig/ml PI for 
analyzing by dual-colour flow cytometry. The FITC intensity represented the relative 
level of cytosolic GFP expression by cells, whereas, PI intensity represented the viability 
status of cells. A) Normal MDA-MB-231 (MDA) cells only. B) A mixed population of 
low (Low-GFP-MDA) and high (High-GFP-MDA) GFP expressing MDA-MB-231 
cells before cell sorting and cloning; High-MDA-GFP cells were then gated and sorted 
by FACSort. C) A population of high GFP expressing MDA-MB-231+GFP 
(MDA+GFP) cells after cell sorting and cloning. 
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Figure 3.4 Histogram plots showing GFP expression. The FITC intensity was due 
to the cell GFP expression. A) Overlay of gated density plots shown in Figure 3.3 
A+B, comparing fluorescence associated with untransfected (MDA) and transfected 
MDA-MB-231 cells prior to sorting and cloning (Low-GFP-MDA & High-GFP-
MDA). B) Overlay of density plots shown in Figure 3.3 A+C, comparing 
fluorescence associated with the untransfected MDA-MB-231 (MDA) and the sorted 
and cloned high GFP expression MDA-MB-231+GFP (MDA+GFP) cells. 
3.3 Levels of cell surface uPA expression of breast and prostate cancer cell lines 
3.3.1 MDA-MB-231, HS-578-T and PC3 cell lines 
High level of cell surface uPA and uPAR expression on the human breast cancer cell 
lines MDA-MB-231 (Ranson et a l , 1998), HS-578-T (Ranson, unpubUshed) and low 
levels of cell surface uPA and uPAR expression on MCF-7 (Ranson et a l , 1998) have 
been shown by flow cytometry. 
In this study, the characteristic high levels of cell surface uPA expression on 
metastatic human breast cancer cell lines MDA-MB-231 and HS-578-T and low level 
of that on non-metastatic cell line MCF-7 were confirmed by dual colour flow 
cytometry. The viable cells were assayed by indirect immunofluorescence labeling of 
cell surface uPA antigen with FITC and detected by dual colour flow cytometry. The 
cell surface uPA expression on metastatic human prostate cancer cell line PC3 was 
also determined. These results are shown in the density plots of FITC intensity vs PI 
intensity (Fig. 3.5) and histogram plots of viable cells only (Fig. 3.6). 
As shown in Figure 3.6, all populations of viable cells in the autofluorescence and 
isotype control have a very low level of FITC intensity which indicated that all four 
cell lines have a low level of FITC-autofluorescence activity and non-specific cell 
surface binding for mouse IgG. As a consequence, this finding implicated that most of 
the FITC intensity observed in the assays would be due to specific labeling of cell 
surface uPA. High levels of FITC intensity were observed in the populations of viable 
HS-578-T, MDA-MB-231 and PC3 cells of the uPA detecting samples (160 ± 10 
M 
fluorescence units for HS-578-T, 86 ± 7 fluorescence units for MDA-MB-231, and 57 
± 3 fluorescence units for PCS, n=3), indicating that these three cell lines express high 
levels of cell surface uPA. Low levels of FITC intensity were found the MCF-7 cell 
line (3 ± 1 fluorescence units, n=3), indicating the MCF-7 cell line had low levels of 
cell surface uPA expression. 
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Figure 3.5 Density plots showing uPA expression of (A) HS-STS-T, (B M D A - ^ ^ 3 1 , C) MCF-7 
and (D) PC3 cells. Cells were incubated with mouse anti-human uPA antibody #394 dO îg/m ), 
washld then incubated with FITC labeled secondary antibody, washed agam 
buffer with PI (5 ng/ml). Cells that excluded PI (i.e. low PI intensity) were gated as Viable cells. (A ), 
(B'), ( C ) and (D') are negative controls for each cell hnes. 
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Figure 3.6 Histogram plots showing cell surface uPA expression of viable (A) 
HS-578-T, (B) MDA-MB-231, (C) MCF-7 AND (D) PC3 cells. The histograms 
were constructed from gated viable cells shown in Figure 3.5. Auto, auto-
fluorescence level of untreated cells. Isotype, mouse anti DNP-P #399 antibody (10 
|Lig/ml). uPA, mouse anti-human uPA antibody #394 (10 jxg/ml). 
3.3.2 MDA-MB-231+GFP cells 
In the case of transfected MDA-MB-231+GFP cells, the expression level of cell 
surface uPA was compared with that of normal MDA-MB-231 cells by indirect 
immunofluorescence staining with PE due to the influence of inherent green 
fluorescence protein. MDA-MB-231 and MDA-MB-231+GFP cells were mixed 
together as samples for the assay. The results are shown in the Figure 3.7 and 3.8. 
Figure 3.7 shows the density plot of FITC intensity vs PE intensity of the (A) 
autofluorescence, (B) uPA-binding and (C) non-specific binding (isotype control) of 
mixed MDA-MB-231 and MDA-MB-231-hGFP cells. The density plots shows that 
each sample contained two distinctive populations of low (2.6 ± 1 fluorescence units, 
n=3) and high (1280 ± 60 fluorescence units, n=3) FITC intensity cells, which reflect 
the MDA-MB-231 and MDA-MB-231+GFP cells, respectively. Similar high levels of 
PE intensity associated with cell surface uPA antigen were observed in both 
populations of cells, compared with low PE intensity levels of auto fluorescence and 
isotype samples in separated histogram plots (Fig. 3.8), indicating that transfected 
MDA-MB-231+GFP cells (44 ± 6 PE fluorescence units, n=3) retain the same high 
expression level of cell surface uPA as the MDA-MB-231 cells (47 ± 5 PE 
fluorescence units, n=3). 
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Figure 3.7 Density plots showing uPA expression on MDA-MB-231 (MDA) and 
MDA-MB-231+GFP (MDA+GFP) cells. The FITC intensity represented the relative 
levels of GFP expression, whereas, PE intensity represented the relative levels of uPA 
expression. A) Auto, auto-fluorescence level. B) uPA, mouse anti-human uPA 
antibody #394 (10 |ig/ml). C) Isotype, mouse anti DNP-P antibody #399 (10 ^tg/ml). 
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Figure 3.8 Histogram plots showing uPA expression on MDA-MB-
231 (MDA) and MDA-MB-231+GFP (MDA+GFP) cells. The 
histogram plots were constructed from density plots shown in Figure 
3.7. A) Overlay of density plots of MDA cells shown in Figure 3.7 
A+B+C. B) Overlay of density plots of MDA+GFP cells shown in 
Figure 3.7 A+B+C. Auto, auto-fluorescence level. Isotype, mouse anti 
DNP-P antibody #399. uPA, mouse anti-human uPA antibody #394. 
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3.4 Levels of cell surface endogenous PAI-2 of breast cancer cell lines 
Due to the time limitation, this study concentrated on the PAI-2 properties of breast 
cancer cell lines. The levels of cell surface endogenous PAI-2 of viable MDA-MB-
231, HS-578-T and MCF-7 cells were determined by indirect immunofluorescence 
labeling of cell surface PAI-2 antigen with FITC and detected by dual colour flow 
cytometry. Dual colour flow cytometric analyses of endogenous PAI-2 expression on 
three cell lines, HS-578-T (A), MDA-MB-231 (B) and MCF-7 (C), are shown in the 
density plots of FITC intensity vs PI intensity (Fig. 3.9) and histogram plots of viable 
cells (Fig. 3.10). In all viable cells expression of endogenous PAI-2 was low 
(fluorescence units after minus isotype control for viable HS-578-T, MDA-MB-231 
and MCF-7 cells are 5.11 ± 0.14, 3.97 ± 0.15 and 0.02 ± 0.01, respectively). A small 
difference between metastatic cells HS-578-T, MDA-MB-231 and non-metastatic 
cells MCF-7 was noted. The higher level of endogenous PAI-2 in non-viable cells 
may reflect the presence of cytosolic form of PAI-2 (Darren Saunders personal 
communication). 
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Figure 3.9 Density plots showing endogenous PAI-2 expression on (A) HS-578-T, (B) MDA-MB-2: 
(C) MCF-7 cells. (A'), (B') and ( C ) are negative controls for each cell lines. Cell were incubated with 
anti-human PAI-2 antibody (mAb #3750, 1:50 dilution) or same concentration isotype mouse anti-
antibody (#399), washed, the incubated with a FITC labelled secondary antibody (1:100 dilution), 
again, and resuspended in buffer with PI (5 |Lig/ml) and analysed by dual-colour flow cytometry. Ce 
excluded PI (i.e. low PI intensity) were gated as viable cells, whereas, cells that uptake PI (i.e. 1 
intensity) as non-viable cells. 
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Figure 3.10 Histogram plots of cell surface endogenous PAI-2 on (A) HS-578-T, 
(B) MDA-MB-231 and (C) MCF-7 cells. The histogram plots were constructed 
from gated viable cells shown in Figure 3.9. Auto, auto-fluorescence level. 
Isotype, mouse anti DNP-P antibody (10 |Xg/nil). PAI-2, mouse anti-human PAI-2 
antibody #3750 (10 |ig/ml). 
3.5 Levels of cell surface exogenous PAI-2 binding of MDA-MB-231 and HS-578-
T metastatic breast cancer cell lines. 
Another important aspect of this study was to determine whether exogenous PAI-2 
could specifically bind to the high level of cell surface bound uPA on metastatic 
cancer cells and be internalized into the cells. The levels of cell surface exogenous 
PAI-2 binding of viable metastatic MDA-MB-231 and HS-578-T cells were assayed 
by direct labeling with FITC-conjugated PAI-2 and detected by dual colour flow 
cytometry. On the low cell surface uPA expressing, non-metastatic MCF-7 cell line 
exogenous cell surface PAI-2 binding was not detectable (data not shown). 
3.5.1 PAI-2 Conjugation 
The uPA binding activities of FITC or TRITC conjugated PAI-2 were examined by 
their ability to form uPA:FITC/TRITC-PAI-2 complexes by SDS-PAGE. A 1:1 molar 
ratio of uPA and PAI-2 or FITC/TRITC conjugated PAI-2 were pre-incubated at 37°C 
for 30 minutes before running the gel. The results for FITC-PAI-2 are shown in the 
Figure 3.11. Lane 4 contains unconjugated PAI-2 monomer at 47 Kda and a PAI-2 
dimer contaminant at 97 Kda. Similar size bands indicative of complexes at 
approximately 80 and 90 Kda were found using unconjugated PAI-2 or conjugated 
PAI-2. The 97 Kda band found in lane 5 which contains uPA and unconjugated PAI-2 
correspond to the PAI-2 dimer contaminant found in lane 4. The uPA-FITC-PAI-2 
complexes and free FITC-PAI-2 were detected under blue light in the same gel, while 
other bands were undetectable. Similar results were obtained with TRITC conjugated 
PAI-2 (data not shown). The concentration of FITC/TRITC conjugated PAI-2 was 
measured by Bio-Rad DC protein assay reagent kit following the manufacture 
instruction. The final concentrations of FITC or TRITC conjugated PAI-2 used in the 
assays were both diluted to Img/ml. 
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Figure 3.11 FITC conjugated PAI-2 forms a SDS-stable complex with uPA as 
well as unconjugated PAI-2. Lane 1 and 2 contained the bands of Bio-Rad's Low 
and High MW SDS-PAGE Standards. Lane 3 contained a sample of uPA. Lane 4 
contained a sample of PAI-2. Lane 5 contained a sample of 1:1 molar ratio of uPA and 
PAI-2. Lane 6 contained a sample of 1:1 ratio of uPA and FITC-PAI-2. (A) gel picture 
under normal light source. (B) gel picture under blue light source. 
3.5.2 Levels of cell surface exogenous FITC-PAI-2 binding 
A time course was firstly carried out to monitor the cell surface exogenous PAI-2 
binding levels of MDA-MB-231 cells. The viable cells were assayed by direct 
inmiunofluorescence labeling with FITC-PAI-2. Therefore, the intensity of FITC 
reflected the level of exogenous PAI-2 binding on cell surface of MDA-MB-231 cells. 
With and without pre-plasminogen activation cells were separately assayed by dual 
colour flow cytometry after 0 hour, 1 hour, 2 hours, 4 hours, 6 hours and overnight. 
Results of viable pre- or non-plasminogen activation cells in different time points 
were compared in the Figure 3.13. 
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Figure 3.12 Cell surface FITC-PAI-2 binding time course of viable 
MDA-MB-231 cells. +plg, pre-plasminogen activated cells (20 
^g/ml, 20 minutes, R.T). -pig, non-plasminogen activated cells. 
Subsequently cells were incubated with 10 |ig/ml FITC-PAI-2 on ice 
in the dark. The maximum FITC intensity was observed at 2-hour 
incubation time point. 
Although only a small difference found between pre-plasminogen activated and non-
activated cells in the time course assay (Fig. 3.12), all cells were pre-activated by 20 
|lg/ml plasminogen to stimulate the specific FITC-PAI-2 binding with cell surface 
bound uPA. Non-specific binding with FITC-BSA was used as control. The specific 
binding of FITC-PAI-2 to uPA was also determined by comparing the cells pre-
incubated with uPA specific inhibitor, i.e. 0.5 mM Glu-Gly-Arg-chloromethylketone 
(EGR-CMK). The viability of the cells was assessed by the PI intensity as described 
in section 3.2. Only viable cells were selected for comparison in histogram plots of 
FITC intensity (Fig. 3.13). 
As shown in Figure 3.13, all populations of viable cells in the autofluorescence and 
BSA control samples have a low level of FITC-autofluorescence activity (between 
1.85 and 4.37 fluorescence units) and non-specific cell surface binding for FITC-BSA 
(between 2.12 and 2.63 fluorescence units). A small increase of FITC intensity was 
found in viable MDA-MB-231 and HS-578-T (19.3 ± 2.1 and 18.2 ± 2.2 fluorescence 
units, respectively, n=3) cells surface. Much higher levels of FITC intensity were 
observed in fixed MDA-MB-231 and HS-578-T (86.2 ± 5.2 and 81.1 ± 5.2 
fluorescence units, respectively, n=3, data not shown) cells, this may due to the 
cytosolic form of PAI-2. Furthermore, a decrease of FITC intensity levels was found 
in viable cells treated with uPA specific inhibitor EGR-CMK, while compared with 
non-EGR-CMK pre-treated samples (difference of fluorescence units were 8.7 ± 0.3, 
and 9.9 ± 0.1 for viable MDA-MB-231 and HS-578-T, respectively). 
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Figure 3.13 Histogram plots of cell surface exogenous FITC-PAI-2 binding of (A) 
viable MDA-MB-231, (B) viable HS-578-T cells. The FITC intensity was due to the 
direct labeling with FITC conjugated PAI-2 (FITC-PAI-2). Cells were pre-activated 
by 20 lig/ml plasminogen to active cell surface uPA, then pre- or non-incubated with 
0.5 mM uPA specific inhibitor EGR-CMK (30 min at RT). Finally cells were 
incubated with 10 |xg/nil FITC-PAI-2 or 10 iig/ml FITC-BSA for 2 hours on ice. Cells 
then were washed, resuspended in buffer with 5 }ig/ml PI, and analyzed by dual colour 
flow cytometry. Auto, auto-fluorescence level; Isotype, FITC-BSA; EGR, EGR-
CMK. 
3.6 Preliminary confocal microscopy to examine exogenous PAI-2 binding and 
internalization by MDA-MB-231+GFP cells 
Flow cytometry showed that exogenous PAI-2 bound specifically to the cell surface 
bound uPA as described in section 3.5. Confocal microscopy techniques allowed 
exogenous TRITC-PAI-2 binding capacity to be visualized on MDA-MB-231+GFP 
cells that were attached and spread onto substrata. Similar results were obtained with 
MDA-MB-231 cells (data not shown). Images were captured on Leica TCS software 
(Figure 3.14). Lower levels of TRITC-PAI-2 binding were found in non-plasminogen 
activated cells (Fig 3.14 A & B), compared to the higher levels found in plasminogen 
activated cells (Fig 3.14 C & D). With time TRITC-PAI-2 binding increased in the 
plasminogen activated cells; compare 5-minute TRITC-PAI-2 incubation (Fig 3.14 C) 
with 15-minute TRrrC-PAI-2 incubation (Fig 3.14 D). Possible internalization of 
TRrrC-PAI-2 (dots indicated by arrows) was only observed in the Figure 3.14 D. This 
effect was first observed at 10 minutes (data not shown). These results visually 
confirmed exogenous PAI-2 was binding to cells presumably via cell surface uPA. In 
order to confirm internalization of TRITC-PAI-2, multiple optical sections will need 
to be performed in future experiments. More experiments using confocal microscopy 
in other cell lines will help us to understand more about PAI-2 and its role in the 
plasminogen activation system of cancer cells. 
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Figure 3.14 Confocal microscopy showing exogenous TRITC-PAI-2 internalization by 
MDA-MB-231+GFP ceils. GFP, MDA-MB-231-KJFP cells. TRITC, TRITC-PAI-2 
(lO^g/ml). Overiay, TRITC-PAI-2 internalization by MDA-MB-231+GFP cells. (A) and 
(B), TRITC-PAJ-2 incubation with non-plasminogen activated cells at 5 and 15 minutes. 
(C) and (D), TRITC-PAI-2 incubation with pre-plasminogen activated cells (20fig/ml, for 
20 minutes at R.T) at 5 and 15 minutes. in (D) indicated positive images of TRITC-
PAI-2 internalization by pre-plasmmogen activated MDA-MB-231+GFP cells. 
3.7 Human breast cancer in vivo nude mice model 
Xenografts of human breast cancer were induced by subcutaneous inoculation of 
2x10^ MDA-MB-231 or MDA-MB-231+GFP cells into the first pair of mammary fat 
pads of 4-week-old nude mice (10 mice for MDA-MB-231 cells, 5 mice for MDA-
MB-2314-GFP cells). Visible tumours 3 mm x 3 mm in dimensions) were observed 
in 27/30 inoculated sites in nude mice after 2 weeks (Fig. 3.15). The growth of 
tumours accelerated when they reached 5 mm x 5 mm in dimensions (around 3-4 
weeks after cell inoculation). The rates of tumour growing were different in individual 
mice, but most tumours reached 10 mm x 10 mm in dimensions before 8 weeks after 
cell inoculation (Fig. 3.16). The phenomenon of angiogenesis around tumour and 
tumour invaded skin were observed in nude mice sacrificed at 4 weeks after cell 
inoculation (Fig 3.17 and 3.18). No visible metastases were observed in major organs 
(lung, liver, spleen, kidney etc.). The abnormal lymph nodes, which are bigger and 
harder than normal lymph nodes, were observed in two sides auxiliary and cervical 
spaces of nude mice. The samples of xenografted tumours, lymph nodes and major 
organs were stored in 10% formalin solution. The preliminary histopathological 
assays confirmed the presence of cancer cells in breast tissues, auxiliary and cervical 
lymph nodes of nude mice (performed by Department of Pathology, St. George 
Hospital, Kogarah). Furthermore, the primary tumour and metastatic cancer cells in 
lymph nodes stained positively for uPA antigen (Fig 3.19) (performed by Dr JL Yang, 
Prince of Wales Hospital, Randwick). Interestingly, two sides of lymph nodes which 
invaded by cancer cells were observed even in the mice that only had one side of 
xenografted tumour (Fig 3.20), which is very similar to distant lymphatic metastases 
of clinical breast cancer patients. The primary tumours induced by MDA-MB-
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Figure 3.15 A visible xenografted breast tumour of a nude mouse. (A) the 
normal breast of a nude mouse; (B) the xenografted breast tumour of a nude 
mouse, 2 weeks after cells inoculation. 
Figure 3.16 Pictures showing xenografted breast tumours in 
nude mice. (A) 6 weeks after inoculation of MDA-MB-231 cells 
(B) 6 weeks after inoculation of MDA-MB-231+GFP cells. 
N o r m a l 
blood 
vessels 
m o u s e 1 . 3 l n t e r n a l ( x 6 
Figure 3.17 Pictures showing angiogenesis in the tumour invaded skin of 
a nude mouse. This mouse, which only had tumour on left side, was 
sacrificed at 4 weeks after cell inoculation. (A) the right side external image 
of the normal skin. (B) the left side external image of the tumour invaded 
skin. (C) the right side internal image of the normal skin. (D) the left side 
internal image of the tumour invaded skin. 
Figure 3.18 Pictures showing angiogenesis (Qi) around the primary 
xenografted breast tumour in a nude mouse. (A) x 6.4 times; (B) x 10 times. 
The mouse was sacrificed at 4 weeks after cells inoculation. 
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Figure 3.19 Histopathological sections showing cancer cells in xenografted primary 
breast tumours and metastatic lymph nodes of nude mice. Paraffin sections were 
stained with uPA mAb #394 (brown) to identify the uPA antigen positive cancer cells. 
(A) primary tumour (HE stain, x 100 times). (B) primary tumour (uPA mAb 
immunohistochemistry staining, x 400 times). (C) metastatic lymph node (uPA mAb 
immunohistochemistry staining, x 100 times). (D) metastatic lymph node 
(immunohistochemistry staining, x 200 times). b cancer cells 
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Figure 3.20 External and correspondence internal view of a nude mouse 4 
weeks post MDA-MB-231 cells inoculated into the mammary fat pad on LHS 
only. Internal view shows presence of enlarged lymph nodes suggesting bilateral 
metastases from the primary tumour. RHS, right hand side. LHS, left hand side. 
LN, lymph node. 
4. DISCUSSION 
The overall aim of this project was to assess the viability of using PAI-2 as a device to 
target a marker of malignant cancer cells i.e. cell bound uPA. This was addressed in 
four major experimental parts: stable transfection, dual colour flow cytometry, 
confocal microscopy and breast cancer animal models. Results of this project built up 
a strong base for further human targeted anti-cancer therapy projects. 
The green fluorescent protein (GFP) gene was successfully transfected into MDA-
MB-231 cells. A new, stable transfected cell line MDA-MB-231+GFP was produced 
after cell sorting and cloning. Compared with MDA-MB-231 cells, a one thousand 
fold increase in green fluorescence intensity was detected in MDA-MB-231+GFP 
cells by flow cytometry. In addition, the GFP expression in these cells was stable even 
in the absence of Geneticin. This suggested that this cell line would not lose its 
capacity to produce GFP when inoculated into mice as a xenograft. Thus the use of 
MDA-MB-231+GFP xenografts may present a good model to follow the metastasis of 
cancer cells, which is similar to the model described in Farina et al. (1998). 
Dual colour flow cytometry was extensively used in this project to determine uPA, 
endogenous PAI-2 expression and exogenous FITC-PAI-2 binding on the cell 
surfaces. The high levels of cell surface uPA expression on metastatic breast cancer 
cell lines MDA-MB-231and HS-578-T compared to low level expression on the non-
metastatic cell line MCF-7 were confirmed. Similarly high levels of uPA expression 
between MDA-MB-231 and MDA-MB-231+GFP cells indicated that the transfected 
cells maintained this important characteristic of metastatic breast cancer cells. The 
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high level of cell surface uPA expression was also observed on the metastatic prostate 
cancer cell line PC3, confirming an association between over-expression of uPA and 
cancer cell metastatic capacity. 
The level of cell surface endogenous PAI-2 was low in all viable breast cancer cells. 
A small difference was found between metastatic (higher endogenous PAI-2) and non-
metastatic (lower endogenous PAI-2) breast cancer cells, agreeing with Western 
blotting observations (Darren Saunders personal communication, data not shown). 
The higher level of endogenous PAI-2 in non-viable cells was noted. This reflects the 
presence of cytosolic form of PAI-2, the function of which is still uncertain (Darren 
Saunders personal communication). Specific binding of exogenous FITC-PAI-2 to 
MDA-MB-231 and HS-578-T cell surface confirmed the observation that PAI-2 
specifically binds to cell surface uPA by Hang et al. (1998). 
The mechanism of PAI-1 internalization into cells via specific uPA binding on cell 
surface has been reported (Cubellis et al., 1990; Conesi and Blashi, 1995). The 
internalization of PAI-2 may be by a similar mechanism. The confocal microscopy 
results visually observed the possible internalization of PAI-2 by MDA-MB-231+GFP 
cells and indicated internalization of PAI-2 most likely via specific uPA binding. Thus 
the use of PAI-2 as a device to target uPA over-expressing malignant cancer cells and 
carry the lethal medicament into these cells is promising. 
Once the ideal targeting marker of malignant cancer cells and targeting device to carry 
the medicament has been established, the challenge of building up an effective human 
cancer metastasis animal model remains in the development of targeted anti-cancer 
therapy. Human breast cancer tumours xenografts were successfully induced in nude 
mice using MDA-MB-231 and MDA-MB-231+GFP cells. Cancer cells were 
identified histologically in sections taken through primary xenografted tumours tissue 
and in nearby lymph nodes (i.e.tumour side axillary lymph nodes) and distant lymph 
nodes (i.e. tumour side cervical and no-tumour side axillary and cervical lymph 
nodes). Furthermore, the positive uPA antigen expression on primary and metastatic 
cancer cells were identified immunohistochemically. 
This lymphatic metastatic model of human breast cancer in nude mice is very similar 
to the human breast cancer metastasis process, which is primarily through the 
extensive lymphatic drainage around the breast (Iglehart, 1997). In results of a 5-year 
national survey by the American College of Surgeons (Nemoto et al., 1980), the 
overall survival rate of female breast cancer patients with and without metastatic 
lymph nodes was 50.9% and 71.8%, respectively, showing the important association 
between lymphatic metastasis and patient survival in breast cancer. Further studies 
using PAI-2-medicament complexes to target and kill metastatic cancer cells in lymph 
nodes may be carried out in this useful animal model, and by using GFP expression 
cancer cells to identify the therapy effects. 
The other important factors in developing targeted therapy include the choices of 
lethal medicament and conjugating reagents to link PAI-2 or other carriers and 
medicament. In the history of targeted anti-cancer therapy, the medicament used to 
conjugate with antibody includes immunotoxins (e.g. ricin, pseudomonas exotoxin, 
diphtheria toxin and their derivatives etc.), anti-cancer drugs (include antimetabolites, 
alkylating agents and intercalating drugs etc.), and traditional beta-emitting 
radioisotopes (Goldenberg, 1993). Although they have produced some improvement, 
the control of metastatic diseases has not been achieved. To achieve the ideal object of 
controlling metastatic cancer growth, we need to find some medicament that has the 
ability to kill all targeted cancer cells effectively at tolerable dose limits (i.e. sparing 
stem cells in marrow while killing metastatic cancer cells), such as short-range 
radioisotopes. 
In conclusion, results of this project explored the promising value of the human 
recombinant PAI-2 and MDA-MB-231-i-GFP cell line in further targeted anti-cancer 
therapy projects (especially in breast cancer). 
^ 
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